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ABSTRACT
As endogenously produced small molecules, hydrogen sulfide (H2S) and carbon monoxide
(CO) have been demonstrated in extensive studies to mediate cellular signaling. More
importantly, the therapeutic effects of these small molecules have been validated in vitro and in
vivo. As such, development of H2S- and CO-based therapeutic agents have attracted great
interests in recent years.
H2S is known to undergo redox transformations in biological systems to produce various
sulfur species such as glutathione persulfide (GSSH) and cysteine persulfide (CysSSH). Several
studies have indicated the enhanced ability for persulfides to modify protein through S-

persulfidation and to quench reactive oxygen species (ROS) as compared with H2S. These
findings raised the potential importance of persulfide species in as a signaling molecule.
Generally speaking, persulfides are not chemically stable for storage under near physiological
conditions. This lack of stability presents difficulties in formulating and delivering such
molecules for research and therapeutic purposes. In Chapter 1, we describe the development of
stable prodrug forms of persulfide for various applications. In doing so, we explored the stability
issues of persulfides under near physiological conditions. The biological activities of these
prodrugs were also examined and compared with that of H2S.
In the field of developing CO as therapeutic agent, ruthenium-based CO releasing molecules
(CO-RMs), CORM-2 and CORM-3, have been widely used as CO surrogates. However, several
previous studies have revealed the ability for such CO-RMs to chemically modify proteins
through CO-independent mechanisms, raising concerns of the suitableness for CORM-2, 3 as CO
surrogates in biological studies. In Chapter 2, we reported our findings on CO-independent
reactivities of CORM-2, 3 toward representative reagents commonly used in various bioassays.
These results suggest the need to carefully de-convolute and interpret the biological data from
relevant experiments using ruthenium-based CO-RMs as surrogates of CO for probing its
biological effects.
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1.1

DEVELOPMENT OF ESTERASE-SENSITIVE PERSULFIDE PRODRUGS

Introduction

(This chapter is mainly based on my publications: Org. Lett. 2018, 20 (20), 6364-6367,
Chin. J. Nat. Med. 2020, 18 (4), 296-307.)
With well-established physiological effects in mammal, Hydrogen sulfide (H2S) is often
referred to as the third gasotransmitter alongside nitric oxide (NO) and carbon monoxide (CO),
though some suggest that they be best termed as small signaling molecules. With the first pKa of
6.88 and second pKa of 19, H2S largely exists in the mono-ionized form under physiological
conditions (pH = 7.4, 37 C). H2S and its ionized forms are easily oxidized in aqueous solution.
The oxidation of H2S is complicated, producing various sulfur species including elemental
sulfur, persulfide, polysulfide, sulfite, sulfate, thiosulfate among other possibilities. Among these
sulfur species, persulfides are emerging as important regulators in sulfur-related cell signaling.
Studies showed more potent activities of persulfides on inducing protein S-persulfidation and
quenching H2O2 as compared with that from H2S. For studying the biological significance of
persulfide species, there are some important challenges. On one hand, persulfides and thiols
exhibit similar chemical reactivities. Tools are needed for selective detection of persulfide,
especially, products of S-persulfidation, which is believed to the mechanism for reactive sulfur
species (RSS) to participate in cellular signaling processes. On the other hand, persulfides are not
chemically stable under near physiological conditions. In order to study their activities in
biological systems, a suitable persulfide delivery system is needed. Below we discussed current
advances related to these two aspects.
1.1.1

S-persulfidation

Protein post-translational modification (PTM) is important in cellular signaling. In terms
of sulfur-related PTM, a cysteine residue of a protein can undergo gluthathionylation,1-4 S-

2
sulfenylation5, 6 and S-persulfidation7-10 under different biochemical and redox conditions. Up to
now, more than 50 proteins have been reported to undergo S-persulfidation as part of PTM,
which is one mechanism through which H2S is involved in cellular signaling.11, 12

Figure 1.1 The proposed mechanism for protein persulfidation induced by H 2S, ROS and
H2S2.

From a chemistry perspective, persulfide can form either from the oxidation of thiol
species or reduction of polysulfide or other species at a higher oxidation state. Others and we
have reported that H2S2 can independently induce S-persulfidation on GAPDH.11, 13, 14 In the
presence of ROS, a thiol group can be oxidized to sulfenic acid or further to sulfinic and sulfonic
acids (Figure 1.1).9 As a simple reducing agent, H2S itself can directly react with oxidative
species to play the role of a quencher. Small polysulfide molecules can also be reduced by H2S to
produce persulfide. More importantly, several studies demonstrated that H 2S can reduce sulfenic
acid to persulfide as a mechanism of reducing oxidative stress since further oxidation to the stage
of sulfinic or sulfonic acid would lead to practically irreversible changes (Figure 1.1).15 In the
cellular environment, the level of H2S and persulfidated proteins are strongly correlated with the
level of oxidative species such as H2O2.
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Figure 1.2 Tag-switch methods for persulfide labeling.

In studying protein persulfidation, it is important to be able to selectively capture or
identify persulfidation site(s). Along this line, several methods have been developed. Methyl
methanethiosulfonate (MMTS) was previously reported to specifically react with thiols rather
than persulfides. However, several studies have shown that persulfides can also react with
MMTS.16, 17 Later it was found that this approach is not selective for persulfidation sites. Another
strategy to detect persulfides first uses iodoacetic acid (IAA) to react with both of thiol and
persulfide residues. Only the disulfide residues formed with IAA can be reduced by dithiothreitol
(DTT) to yield the free thiol group, but not the product from thiol and IAA. This two-step
process allows for the labeling of the thiol product from DTT reduction, and thus unequivocally
identify the persulfidation site. In 2014, Xian and coworkers developed a two-steps tag-switch
method for detection of protein S-persulfidation (Figure 1.2).18 In the first step, a thiol-blocking
reagent, methylsulfonyl benzothiazole (MSBT) can be used to block thiol and persulfide
residues. Then a cleverly designed carbon-based nucleophile, methyl cyanoacetate (MCA) is
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used to selectively tag the disulfide intermediate by removing the MSBT moiety. In solution
studies, the yield of MCA and a derivative of cysteine disulfide intermediate was shown to be
98%. Using a model protein, bovine serum albumin (BSA), it was shown that the method was
able to selectively detect persulfidation modifications among other possibilities such as sulfenic
acid (BSA-SOH), thiol (BSA-SH) and glutathionylation modification (BSA-SSG). Further
studies in cell lysates using Jurkat cells, elevated levels of persulfidation of Hsp70 and GAPDH
were detected after treatment of the cells with H2S for 30 min. Along a similar line, Filipovic
and coworkers developed another tag-switch method for detection of protein persulfidation by
using a different blocking reagent and nucleophilic tag molecule (Figure 1.2).15 In their design,
4-chloro-7-nitrobenzofurazan (NBF-Cl) was used to react with sulfur-related nucleophilic
species including thiol (-SH), sulfenic acid (-SOH) and persulfide (-SSH). In the next step,
dimedone was used to selectively attack the disulfide bond formed between persulfide and NBFCl to achieve selective labeling.
1.1.2

Literature persulfide donors

It is very important to note that persulfidation cannot happen with hydrogen sulfide per
se. It has to be converted to a species at a higher oxidation state, e.g. persulfide. It is believed that
increased persulfidation in the presence of hydrogen sulfide is at least partially the result of
increased “sulfur pool” and subsequent oxidation to a higher oxidation state, which allows for
persulfidation to happen. Alternatively, cysteine thiol can be oxidized to sulfenic acid, which can
be converted to persulfidation product by reaction with H2S (Figure 1.1). Then there is the
question of whether delivering sulfur species at the persulfide state would offer more efficient
persulfidation in solution, in vitro, and in vivo. With such thinking in mind, there have been
efforts in making prodrugs and donors of persulfides.
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Figure 1.3 Esterase-sensitive persulfide prodrugs.

A series of esterase-sensitive persulfide prodrugs was developed in our lab (Figure 1.3)
by taking advantages of an unstable "hydroxymethyl disulfide" intermediate.16 After the removal
of the ester masking group from the donor, the persulfide is released from the decomposition of
the "hemiacetal" intermediate. By varying the steric hindrance on the masking ester group, we
were able to tune the half-lives of the prodrugs from 12 to 145 s in the presence of 1 U PLE/mL.
For analysis of the release yield, persulfide was directly trapped by an electrophile,
dinitrofluorobenzene (DNFB), to give yields in the range of 82% to 92%. Models of heart
myocardial infarction reperfusion (MI/R) injury are commonly used to assess the effectiveness of
sulfur donors in reducing damage size as measured by infarct size per area-at-risk ratio. In
assessing the effectiveness of the persulfide donors described, it was found that treatment with
50-100 µg kg-1 of the prodrug BW-HP-202 was able to significantly decrease the infarct size per
area-at-risk.
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Figure 1.4 pH- and fluoride-sensitive persulfide prodrugs.

Xian and coworkers also utilized an unstable "hydroxy methyl" disulfide intermediate to
release persulfides (Figure 1.4).19 Specifically, TMS and TES protecting groups were used as
acid- or fluoride-sensitive moieties. In DMF/PBS buffer (4:1), at pH 7.4, for prodrug 4a, the total
decomposition required 10 h, while at pH 2.5, it required 2.5 h to achieve total consumption of
the prodrug. Persulfide trapping with iodoacetamide in pure methanol was used. In the presence
of KF, the trapping yields for benzyl and protected cysteine persulfides from donor 4b and 4c
were 94% and 38% respectively. Toscano presented a precursor of modified cysteine persulfide
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based on S-substituted-thioisothioureas.20 The terminal sulfhydryl moiety of the persulfide was
protected in a S-alkylthioisothiourea form. Under physiological conditions, the precursor 4d was
designed to initiate deprotonation followed by an elimination reaction to produce persulfide and
thiourea derivative (Figure 1.4). However, the persulfide seemed to prefer undergoing a trapping
reaction with itself instead of the trapping reagent, N-ethylmaleimide (NEM). To overcome selftrapping, a gem-dimethyl moiety was installed next to the inner sulfur atom to prevent the selfperturbation of persulfide species. Then the persulfide trapping yield of prodrug 4e improved to
96% with 20 mM NEM in pH 7.4 PBS buffer containing 10% D2O.

Figure 1.5 ROS-sensitive persulfide prodrugs.

Several ROS-sensitive persulfide prodrugs have also been reported. Matson and
coworkers used an 1,6-elimination system to release N-acetyl cysteine (NAC) persulfide (Figure
1.5).21 An aryl boronic ester was used as a latent hydroxyl group, generation of which is
dependent on reaction with H2O2. Further, the formation of the hydroxyl group initiates selfimmolation, leading to NAC persulfide and p-hydroxy-benzyl alcohol. The NAC persulfide was
directly detected by LC-MS. 200 µM of the donor 5a was shown to improve cell survival of
H2O2-induced death from 30% to 100%. It should be noted that the control compound, which
only contains aryl boronic ester group, was also able to increase the cell viability to around 70%.
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Chakrapani and co-workers also reported a ROS-sensitive benzylpersulfide donor using the
boronate approach. Upon removal of the vinyl boronate ester by H2O2, the unstable enolate
intermediate 5d can undergo a 1,4-O,S-relay to generate benzyl persulfide and byproduct
cinnamaldehyde (Figure 1.5).22 In the presence of 10 equiv of H2O2, the decomposition rate
constant of donor 5c was determined to be 5.3  10-2 min-1. However, it was suggested that
byproduct cinnamaldehyde could also react with benzyl persulfide, complicating the
interpretation of the results somewhat. The donor (5c) was also examined on its protective
effects toward DLD-1 cells under oxidative stress. In the presence of 50 M of an oxidative
stress inducer, menadione, 100 M of 5c increased the cell viability from 30% to 70%. The
control compound, which only bears the aryl boronic ester group, did not show any protective
effect.

Figure 1.6 Photo-sensitive persulfide prodrugs.

Singh and coworkers reported a strategy to develop photo-sensitive persulfide prodrugs
by using a well-known ortho-nitrobenzyl (ONB) phototrigger.23 As shown in Figure 1.6, the
terminal sulfhydryl group on NAC persulfide was protected by ONB. Upon light irradiation ( 
365 nm), ONB group was removed from prodrugs 6a and 6b followed by the release of NAC
persulfide. The decomposition of 6a and 6b was studied in ACN/PBS (3:7) by HPLC; and their
quantum yields were determined to be 0.07 and 0.36 respectively. In order to quantify the release
of NAC persulfide from the prodrugs, DNFB was used as a direct trapping agent. In the presence
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of 5 mM DNFB, 57 and 59 M of NAC persulfide were detected from prodrugs 6a and 6b,
respectively, after photolysis. The prodrugs were further examined for their anti-oxidation
ability. Under light irradiation for 30 min, incubation of 200 M of 6a with Hela cells increased
cell viability from 50% to 70% after H2O2 treatment.
Overall, a good number persulfide prodrugs with triggered release have been reported in
recent years. Most of them have been examined for their anti-oxidation effect at the cellular
level, suggesting improved protective effects over that of the corresponding thiol.

1.1.3

Current challenges in developing persulfide prodrugs

Although, several persulfide donors have been reported with demonstrated biological
activities, there are still some issues remaining to be resolved. First, for distinct biologically
relevant persulfides (GSSH, CysSSH), no donor is available for studying their activities. GSSH
was said to be the most abundant persulfide species in the physiological environment, and was
shown to have strong H2O2-scavenging ability.24 It might imply the importance of GSSH in
cellular antioxidant defense. Currently, the generation of GSSH mostly depends on redox
reactions involving H2S with GSSG.25, 26 However, the presence of H2S in the mixture limits
their applications for exploring functions of GSSH other than H2S. Tools are needed for
delivering pure GSSH to biological systems. Second, the stability of persulfide species has not
been studied under physiological conditions. Understanding the stability and degradation profiles
of persulfides would be important for answering the questions related to their mechanism of
actions.
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In this chapter, we discussed our efforts in developing a general prodrug strategy to store
and deliver GSSH and various other persulfides for helping understand the above-referenced
issues.

1.2

Results and discussions
1.2.1

Design of a GSSH prodrug

To prepare a donor of unprotected GSSH, one key issue is developing a synthetic route,
which can tolerate the free amino and carboxylic group. Thus, we first built a reactive disulfide
bond by treating GSH with 2,2'-dipyridyldisulfide,27 which was further treated with thiol acid
BW-HP-101 to afford GSSH donor BW-GP-401(401), a stable odorless white powder (Figure
1.7, see Experimental part). Using this route, we protected the outer sulfur of the persulfide
group, and caged it as a thioester, which has an esterase-sensitive trigger using a “trimethyl lock”
system.28 After the removal of the protecting group by an esterase, the phenol hydroxyl group is
expected to undergo lactonization to release GSSH (Figure 1.7). Several reasons were
considered for choosing this system. Previously, we have used this strategy to release H2S and
H2S2 and the chemistry is well understood.29, 30 Additional factors that control the release rates
have been extensively studied.29 Different masking groups on the phenol hydroxyl group should
allow for tuning the release rates, and on-demand and selective prodrug activation.29, 30 The
prodrug moiety can also be used to improve stability and water solubility.30 The byproduct
lactone is a nontoxic and stable molecule that helps to minimize potenti issues in application in
biological systems.30
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Figure 1.7 Synthesis and release mechanism of BW-GP-401.

1.2.2

Validation of GSSH release

We first examined the release of GSSH from 401. Since GSSH is unstable for detection
under physiological conditions, we studied the release kinetics by using HPLC to monitor
lactone formation. Specifically, 100 µM 401 was incubated with 2 unit/mL porcine liver esterase
(PLE) at 37 ºC. At different time points, the generation of the lactone was analyzed by HPLC.
After 10 min, the donor peak became almost undetectable. As shown in Figure 1.8B, at the 30min time point, the lactone peak corresponded to over 80% conversion. To verify that triggeredrelease only happens in the presence of PLE, we also incubated the GSSH donor in phosphatebuffered saline (PBS) without introducing PLE; no lactone was detected and the donor peak
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remained about the same area over a period of 2 h, the maximal time of incubation period
studied.
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Figure 1.8 A) Activation of 401 and subsequent GSSH trapping by DNFB; B) Released
lactone was detected by HPLC. n = 3; C) Trapped product A was monitored by HPLC. n = 3.

To further validate the release, we used a trapping reagent to directly capture GSSH from
401. Unlike H2S and H2S2,31, 32 no specific probe has been developed to detect GSSH.
Previously, our laboratory used 2,4-dinitrofluorobenzene (DNFB) to trap benzyl persulfide with
a yield of over 80%.16, 33 In this study, we also used DNFB to trap GSSH (Figure 1.8A). To fully
consume 401 within a short period of time, 10 unit/mL PLE was added to the solutions of 401 at
100, 200, and 400 µM with 2 mM DNFB. The resulting mixture was allowed to be incubated for
30 min at 37 °C. The generation of the trapped product A was analyzed by HPLC (Figure 1.8C).
For the purpose of quantitative analysis of the trapped product A, the standard compound was
synthesized (see Experimental part). Different concentrations of 401 gave various amounts of
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trapped product A, Specifically, about 12 µM, 18 µM and 45 µM GSSH (~10%) were detected
by treating with 100 µM, 200 µM and 400 µM of 401 with 10 unit/mL PLE, respectively
(Figure 1.8C). Since the trapping method has been successfully applied to benzyl persulfide
with high yield,16 the low trapping efficiency might be due to the unstable nature of GSSH under
physiological conditions and/or further scrambling by other thiol species present. It has been well
accepted that the general stability of persulfide species is poor.34 Only a limited number of small
molecule persulfide species has been obtained and partially characterized.35-39 In the trapping
process, there is a competition between trapping and decomposition of the persulfide species
through disproportionation. To further identify the products from GSSH, we used mass
spectrometry to analyze the incubation solution and found the increasing relative intensity of a
peak attributed to GSSSG as the release reaction progressed (Figure 1.9 and 1.10).

Figure 1.9 LRMS of the reaction mixture between A) 0 to 1 min; B) 5 to 6 min; C) 29 to
30 min.
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Such results further suggest GSSH disproportionation as a contributing factor for the low
yield in the trapping experiments. As an effort to minimize the bimolecular disproportionation
reaction, we conducted additional release experiments using a lower level of 401 (5 µM) and
PLE (1 unit/mL) and was able to achieve 34 ±3% yield of the trapped product with the remaining
mass balance being predominately GSSSG.

Figure 1.10 Relative intensity of the peaks corresponding to A) 401 and B) GSSSG over a
period of 30 min.

H2S was considered to be one of the products from persulfide through disproportionation
(Figure 1.11A).34, 39 Compound 401 provides a chance to study the H2S release from pure
GSSH. In this case, 200 µM of 401 was incubated in PBS containing 10 unit/mL PLE. The
methylene blue (MB) method was used to probe H2S generation. 50 µM of H2S was detected
from 200 µM of 401 between 2 and 10 min (Figure 1.11B). In the control group without PLE,
no generation of H2S was observed within 10 min (Figure 1.11B and 1.12). In a biological
environment, the level of cysteine or other free thiol groups is high.24 GSSH is known to quickly
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react with thiol and yield the disulfide byproduct and H2S (Figure 1.11A).34, 40 We then applied
2 mM NAC into the same system used above. At the 2-min point, the H2S level reached a peak
concentration of 115 µM, and then decreased to 28 µM at the 10-min point (Figure 1.11B). It
should be noted that the peak concentration for a gasotransmitter generated from a prodrug is a
different concept as compared to the maximal concentration for a non-volatile drug generated
from a prodrug.41, 42 We have demonstrated in the past that a peak concentration at 50% of the
prodrug concentration was about the highest that one can achieve from a H 2S donor.29 Thus, it is
reasonable to assume that the generation of 115 µM of H2S represents a near quantitative
reaction. The G-SS-NAC disulfide byproduct was also quantified by mass spectrometry, and the
yield was 38% (see Experimental part). There is a clear discrepancy between H2S production
and G-SS-NAC formation in quantity. This is easy to understand because of the scrambling
effect of the existing thiol (excessive NAC) species, which can react with G-SS-NAC to give
GSH and NAC disulfide.
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Figure 1.11 A) H2S was released from 401 with or without NAC; B) H2S detection by the
MB method. n = 3.

In this case, we also quantified the GSH in the system, and the yield was about 77% (see
Experimental part). All these explains the mass balance issue. However, in the absence of PLE,
H2S was not detectable at the 10-min point with exposure to a high concentration of NAC
(Figure 1.11A and 1.12). The results further demonstrate the need for an esterase to trigger the
release of GSSH from 401, supporting the instability of GSSH and the stability of the prodrug
under physiological conditions. Further, the relative low trapping yield of GSSH and the high
conversion yield in the reaction with NAC give further hint on why nature “chose” GSSH as a
reagent for protein thiol modification.
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Figure 1.12 Detection of MB by UV spectrometry.

1.2.3

Biological activities of the GSSH prodrug

It has been reported that RSSH can regulate the activity of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) through S-persulfdation.43, 44 We previously applied our H2S2 donor on
GAPDH and confirmed the correlation between elevated protein sulfhydration levels and
decreased enzyme activity.30 In the physiological environment, GSSH was said to be the most
abundant small molecule persulfide and may also be involved in the regulation of GAPDH
activity.24, 43, 44 To explore this aspect, GAPDH was incubated with 100, 50 and 25 µM of 401,
respectively, for 30 mins in the presence of 10 unit/mL PLE. Then its catalytic activity was
determined. Compared to the vehicle group, the catalytic ability decreased to 62 ±1%, 44 ±9%
and 37 ±8% of the maximal activity, respectively (Figure 1.13). A control group treated with the
lactone did not show any effect on GAPDH activity. To see if the decreased activity was caused
by persulfdation, 2 mM dithiothreitol (DTT), which can reduce the persulfide group to a thiol
residue, was added to each group. A significant increase in activity was observed after incubation
for another 2 h at room temperature (Figure 1.13). According to the above results, GSSH can
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also inhibit the activity of GAPDH and might acts as a redox regulator participating in regulating
cellular metabolism.
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Figure 1.13 Inhibition of GAPDH activity by 401. 2 µg/mL GAPDH was incubated with
various concentration of 401 or 100 µM lactone for 0.5 h with 10 unit/mL PLE and 1% DMSO,
after which the enzyme activity was measured. Each group was then incubated with 2 mM DTT
at rt for 2 hours before the measurement of GAPDH activity. n = 3. *P < 0.01 for the
comparison with the vehicle group. #P < 0.05 for the comparison with the group before DTT
treatment.

GSSH was found to be more potent in providing cytoprotective effects in highly
oxidative cellular environment than GSH or H2S.24 In an effort to probe this point, we used 401
to rescue cells in highly oxidative environments. We first tested the cytotoxicity of 401 on H9c2
cells; no obvious toxicity was observed at 200 µM after 24 h of incubation (Figure 1.14). We
next treated cells with 50, 100 and 150 µM 401 before exposure to H2O2 (Figure 1.15). Without
treatment with 401, after the incubation with 450 µM H2O2, cell viability was reduced by 60%
compared with vehicle group. In the presence of 401, this reduction in viability was less than
40% and was concentration dependent (401). Meanwhile, the byproduct lactone failed to rescue
cells from H2O2. H9c2 cells were also treated with GSH and Na2S before adding H2O2. However,
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no obvious increase in viability was observed (Figure 1.15). The above results further support
the fact that GSSH is more effective than GSH and H2S in protecting cells from highly oxidative
environment, which might indicate its unique property in defending cellular oxidative stress.
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Figure 1.14 Cytotoxicity of 401. H9c2 cells were treated with 401 at various
concentrations. After 24 h incubation, cell viability was determined by Cell Counting Kit-8. Cell
culture media has 1% DMSO.
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Figure 1.15 Effects of different concentrations of 401 or various controls and relevant
compounds on H9c2 cell line in the presence of H2O2. Prior to incubation with H2O2 (450 µM)
for 3 h at 37 ºC (except for vehicle group), H9c2 cells were treated with 1) Blank control; 2) 150
µM Na2S; 3) 150 µM lactone; 4) 150 µM GSH; 5) 50 µM 401; 6) 100 µM 401; 7) 150 µM 401
for 1 hour at 37 ºC. Cell viability was measured by Cell Counting Kit-8 (CCK-8). n = 3. *P <
0.01 for the comparison with group 1. #P < 0.01 for the comparison with group 5.
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1.2.4

Design of a general persulfide delivery system

Based on studies of the esterase-sensitive GSSH prodrug, we envisioned this system
being adapted to be a universal delivery system for various persulfide species. As such, four
persulfide donors BW-PP-501 to 504 (PP-501 to 504) that release distinct persulfides were
synthesized (Figure 1.16, see experimental part). Upon the hydrolysis of the ester bond by an
esterase, the unmasked phenol group would go through lactonization to release the caged
persulfide (Figure 1.16).

Figure 1.16 Persulfide prodrugs synthesized in this study and their release mechanism.
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1.2.5

Validation of persulfide species release

Figure 1.17 Detection of the released persulfides by trapping with DNFB and structures
of R-SS-DNFB.

In this case, we also chose to used dinitrofluorobenzene (DNFB) to trap the released
persulfides in a relatively stable disulfide (R-SS-DNFB) form for detection purpose (Figure
1.17). All trapped products R-SS-DNFB were synthesized as standards for quantifying the
persulfide release yield from the respective prodrugs (see Experimental part). Specifically, 25
µM of a persulfide prodrug was incubated with 10 units/ml esterase from porcine liver (PLE) and
10 mM DNFB for 30 min in PBS buffer (pH = 7.4) at 37 °C. The trapped product R-SS-DNFB
was then quantified by HPLC. Using this method, all 4 persulfide donors led to a relatively high
yield of R-SS-DNFB formation, between 76 to 94 % (Table 1.1, Figure 1.18-1.21). Lactone
formation was also observed by HPLC (Figure 1.18-1.21). This high yield of R-SS-DNFB
formation indicates the efficient release of the persulfide from the prodrug. In contrast, no
persulfide was released after 30 min of incubation in PBS without PLE, showing the esterasesensitive nature of persulfide release.
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Table 1.1 Trapping yield of various persulfides released from the prodrugs by DNFB (n
= 3).
Prodrugs
Trapping yield (%)

501

502

503

504

84.2±1.9

94.0±1.3

77.5±2.0

76.0 ± 2.8

Figure 1.18 N-CysSSH released from PP-501 was trapped by DNFB for detection
purpose. HPLC chromatograms of synthesized N-Cys-SS-DNFB (black line) and the released NCysSSH from 25 µM PP-501 trapped by DNFB (pink line). 25 µM PP-501 was incubated with
10 units/mL esterase from porcine liver (PLE) and 10 mM DNFB in phosphate-buffered saline
(PBS, pH 7.4) for 30 min at 37 °C. The trapped product N-Cys-SS-DNFB was then quantified by
HPLC (pink line). The synthesized N-Cys-SS-DNFB was used as reference standard for
detection/quantification purpose.

Figure 1.19 Propyl persulfide released from PP-502 was trapped by DNFB for detection
purpose. HPLC chromatograms of synthesized propyl-SS-DNFB (black line) and the released
Propyl persulfide from 25 µM PP-502 trapped by DNFB (pink line). 25 µM PP-502 was
incubated with 10 units/mL esterase from porcine liver (PLE) and 10 mM DNFB in phosphatebuffered saline (PBS, pH 7.4) for 30 min at 37 °C. The trapped product propyl-SS-DNFB was
then quantified by HPLC (pink line). The synthesized propyl-SS-DNFB was used as reference
standard for detection/quantification purpose.
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Figure 1.20 Benzyl persulfide released from PP-503 was trapped by DNFB for detection
purpose. HPLC chromatograms of synthesized benzyl-SS-DNFB (black line) and the released
benzyl persulfide from 25 µM PP-503 trapped by DNFB (pink line). 25 µM PP-503 was
incubated with 10 units/mL esterase from porcine liver (PLE) and 10 mM DNFB in phosphatebuffered saline (PBS, pH 7.4) for 30 min at 37 °C. The trapped product benzyl-SS-DNFB was
then quantified by HPLC (pink line). The synthesized benzyl-SS-DNFB was used as reference
standard for detection/quantification purpose.

Figure 1.21 CF3 Benzyl persulfide released from PP-504 was trapped by DNFB for
detection purpose. HPLC chromatograms of synthesized CF3 benzyl-SS-DNFB (black line) and
the released CF3 benzyl persulfide from 25 µM PP-504 trapped by DNFB (pink line). 25 µM PP504 was incubated with 10 units/mL esterase from porcine liver (PLE) and 10 mM DNFB in
phosphate-buffered saline (PBS, pH 7.4) for 30 min at 37 °C. The trapped product CF3 benzylSS-DNFB was then quantified by HPLC (pink line). The synthesized CF3 benzyl-SS-DNFB was
used as reference standard for detection/quantification purpose.

1.2.6

Stability studies of the various persulfide species

This high-yield formation of R-SS-DNFB indicates: 1) this system can almost
quantitatively generate pure persulfide species and 2) DNFB can effectively trap persulfide
species as R-SS-DNFB for detection purpose. These two key points forms the foundation of the
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following persulfide stability studies, which need 1) a donor system to efficiently deliver a pure
persulfide and 2) a detection method to quantify the persulfide. With this persulfide prodrug
system and quantification method in hand, we then studied the stability of various persulfides in
PBS (pH = 7.4) at 37 °C. Briefly, 25 µM of a prodrug was incubated with 20 units/ml PLE in
PBS at 37 °C. At different time points, aliquots of the reaction mixture were extracted and
reacted with 10 mM DNFB for 30 min. The trapped product R-SS-DNFB was then quantified by
HPLC. In the presence of a high concentration (20 units/ml) of PLE, 25 µM of persulfide
prodrugs were fully consumed within 10 s of incubation at 37 °C, suggesting the release of the
persulfide species was also completed under these conditions. As such, we started at 10 s-time
point to monitor the concentration of persulfides in PBS solution. For PP-501, at 10 s, there was
13 µM N-acetyl-L-cysteine persulfide (N-CysSSH) remaining and within 1 min, the N-CysSSH
concentration dropped below 5 µM due to degradation (Table 1.2). Other persulfide species
released from PP-502 to 504 also showed similar patterns under similar conditions (Table 1.2).
As demonstrated here, persulfide species are very unstable in PBS at 37 °C, the concentration of
persulfide released from 25 µM prodrugs would quickly drop below 5 µM within 60 s.
Table 1.2 The concentrations of the trapped product R-SS-DNFB from different
persulfide prodrugs at different time points.
Time
Conc. of the trapped product (µM)
(s)

PP-501

PP-502

PP-503

PP-504

10

13.2

14.6

11.3

10.8

20

8.9

10.1

5.4

7.4

30

5.6

8.1

4.1

6.1

40

4.9

7.3

4.0

5.6

50

3.8

6.2

3.0

5.3

25
60

3.1

4.7

2.6

4.5

After observing the quick degradation of persulfide species, we were motivated to study
the degradation profile. We chose to use PP-501 to probe the degradation profile of N-CysSSH
under near phycological conditions. Specifically, 100 µM PP-501 was incubated with 10
units/ml PLE in PBS at 37 °C for 30 min to fully complete the release and degradation of NCysSSH. By using the methylene blue method, around 15 µM of H2S was detected in the
reaction solution. In contrast, almost no H2S was formed in the absence of PLE. Hydrogen
polysulfide (H2Sn, n ≥ 2) was also produced due to the degradation of N-CysSSH as revealed by
a H2Sn selective fluorescence probe DSP-3 (Figure 1.22B).45 Compared to the positive control
group (Na2S2), nearly 10 µM of H2Sn was generated in the degraded reaction mixture based on
increase of the fluorescent intensity from DSP-3. Other degradation products include disulfide,
trisulfide, tetrasulfide and free thiol are identified by mass spectrometry in the reaction mixture
(Figure 1.22C, 1.23). At this point, we have identified several sulfur species with different
oxidation states in the degradation mixture of N-CysSSH. These observations show that,
although the scrambling effect leads to a quick decomposition of N-CysSSH, sulfane sulfur
species include H2Sn, trisulfide and tetrasulfide still remain in the mixture, which might indicate
the “overall oxidation state” of persulfide is maintained at certain degree.
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Figure 1.22 Degradation study of N-CysSSH released from PP-501. A). 100 µM PP-501
was incubated with 10 units/ml PLE or without PLE at 37 °C for 10 min in PBS, after that, the
H2S concentrations were quantified by methylene blue method. Values are means ± SD. n = 3;
B). 100 µM PP-501 was incubated with 10 units/ml PLE at 37 °C for 10 min in PBS, H2Sn
production was determined by DSP-3, Na2S2 was used as the positive control, background
fluorescent intensity was recorded as vehicle group. Values are means ± SD. n = 3; C).
Illustration of the degradation products of N-CysSSH.

Figure 1.23 Degradation study of N-CysSSH released from PP-501 examined by MS. 100
µM PP-501 was incubated with 10 units/mL PLE at 37 °C for 10 min in 10 mM NH4HCO3
buffer. Then, the degradation product was examined by MS.
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1.2.7

Cytoprotective effects of persulfide prodrugs

Next, we were interested in testing the effects of these persulfide prodrugs in protecting
cells from oxidative stress. To allow complete release of persulfide from the prodrugs, H9c2
cells were pretreated with 100 µM of various prodrugs for 1 hour with 1 unit/ml PLE at 37 ºC.
Cells were then challenged with 500 μM H2O2 for 4 hours followed by determining cell viability.
As shown in Figure 1.24, all persulfide donors (PP-501 to 504) pretreated group elevated the
cell viability from 30 % to around 60 %, and Na2S treated group didn’t show significant
protective effect. Additionally, we did not observe significant potency differences among the
different persulfide donors. These results are consistent with our observations on cytoprotective
studies of the GSSH prodrug, indicating a more potent antioxidative effect of persulfides
compared to that from H2S.
***

Viability/%

100
80
***

60

***

**

***

40
20

N
on
e

2S

N
a

H

2O
2
Ve
ic
hl
e
PP
-5
01
PP
-5
02
PP
-5
03
PP
-5
04

0

Figure 1.24 Cytoprotective effect of various persulfide donors against H 2O2 induced
damage. H9c2 cells were pretreated with various compounds for 1 hour with 1 unit/ml PLE, then
cells were challenged with 500 μM H2O2 for 4 hours. After that, the cell viability was
determined. “None H2O2” group means cells were not challenged with H2O2. Values are means
± SD. n = 3, *P<0.05, **P<0.01, ***P<0.001 versus the vehicle group.
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1.3

Conclusion
In conclusion, we have developed an esterase-sensitive prodrug system to deliver various

persulfide species under near physiological conditions. The release of persulfides were validated
by the formation of byproduct lactone and direct trapping with DNFB. Using these persulfide
prodrugs, we studied the stability and degradation of GSSH and N-CysSSH. In a biological
context, we examined those persulfide prodrugs in the inhibition of GAPDH activity and
cytoprotective effects against oxidative damage. Taken together, we provide the chemistry that
helps storing and delivering persulfide species for studying their biological relevance. However,
we should also note that the easy scrambling process involving persulfide means that the
concentration and time-scale make a difference in the experimental outcome when designing
biological studies.
1.4

Experimental part
1.4.1

General information

All reagents and solvents were of reagent grade and purchased from commercial
suppliers (Sigma Aldrich, VWR International, Oakwood Chemicals and Fisher Chemicals). 1H
(400 MHz) and 13C (100 MHz) NMR spectra were recorded on a Bruker-400 spectrometer. Mass
spectrometric analyses were performed on a Q-TOF micro (Waters Micromass) mass
spectrometer. HPLC analyses were performed on a Shimadzu Prominence UFLC (column:
Waters C18 3.5 μM, 4.6×100 mm). UV-Vis absorption spectra were recorded on a Shimadzu
PharmaSpec UV-1700 UV-Visible spectrophotometer. Purification was performed on a
Shimadzu HPLC (column: Waters Semi-Prep Column, 20×250 mm). 96-well plates were read
and recorded on a PerkinElmer 1420 multi-label counter. Porcine liver esterase (PLE) was
purchased from Aldrich (E3019). Lactone was synthesized according to a literature procedure. 28
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BW-HP-101 was synthesized according to literature procedures.29 The H2Sn selective
fluorescence probe, DSP-3, was synthesized according to literature procedures.45
1.4.2

Synthesis of the GSSH prodrug and trapped product A
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Figure 1.25 Synthesis of N5-(1-((carboxymethyl)amino)-1-oxo-3-(pyridin-2yldisulfanyl)propan-2-yl)glutamine (a).
Synthesis of N5-(1-((carboxymethyl)amino)-1-oxo-3-(pyridin-2-yldisulfanyl)propan-2yl)glutamine (a). To a solution of L-glutathione (463 mg, 1.11 mmol) in H2O (8 mL) and
methanol (8 mL) was added 4,4′-dithiodipyridine (490 mg, 2.22 mmol). The mixture was stirred
at room temperature for 13 h. Then methanol was removed from the reaction mixture under
reduced pressure. The residual solution was washed with dichloromethane (5 x 10 ml), and then
evaporated under reduced pressure to give the crude product (368 mg), which is a light yellow
solid. The crude product was used for next step without purification.46
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Figure 1.26 Synthesis of BW-GP-401.
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Synthesis of N5-(3-((3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoyl)disulfanyl)-1((carboxymethyl)amino)-1-oxopropan-2-yl)glutamine (BW-GP-401). To a solution of a (368 mg)
in PBS (3 ml) was added dropwise BW-HP-101 (110 mg, 0.39 mmol) in THF (1 ml). The
mixture was stirred at room temperature for 2 h. Then THF was removed from mixture under
reduced pressure. The aqueous residue was directly purified by RP-HPLC to yield a white solid
(152 mg, 66%). 1H NMR (CD3OD): 6.84 (s, 1H), 6.62 (s, 1H), 4.46 (dd, J = 8.8, 5.0 Hz, 1H),
3.90 (s, 2H), 3.83 (t, J = 6.3 Hz, 1H), 3.29 (d, J = 1.5 Hz, 2H), 2.98 (ddd, J = 22.8, 13.9, 6.9 Hz,
2H), 2.62-2.43 (m, 5H) ,2.32 (s, 3H), 2.19 (d, J = 15.4 Hz, 3H), 2.15 (q, J = 6.8 Hz, 2H), 1.57 (s,
6H). 13C NMR (CD3OD): 197.4 174.4, 172.5, 172.4, 171.7, 150.9, 139.2, 137.7, 133.7, 133.9,
124.3, 56.1, 53.6, 49.6, 41.7, 41.0, 32.4, 32.1, 32.0, 27.0, 25.6, 21.9, 20.2. HRMS calculated for
C25H36N3O9S2 [M+H]+: m/z 586.1893 found 586.1902.
O 2N

O
HOOC
NH2

N
H

SH
H
N

S

NO2

O

DMF/DCM
HOOC
r.t.

O

S
S

Cl

COOH +
NO2

NH2

NO2

N
H

H
N

COOH

O

Trapped product A

Figure 1.27 Synthesis of trapped product A.
Synthesis of N5-(1-((carboxymethyl)amino)-3-((2,4-dinitrophenyl)disulfanyl)-1oxopropan-2-yl)glutamine (trapped product A). To the solution of 2,4-dinitrobenzenesulfenyl
chloride (38 mg, 0.161 mmol) in anhydrous DCM (1ml) was added dropwise L-glutathione (67
mg, 0.16 mmol) in DMF (10 ml). The mixture was allowed to stir at room temperature under the
protection of nitrogen. After 1 h, the mixture was concentrated to 3 ml in DMF, and directly
purified by RP-HPLC to give the product as white solid (35 mg, 43%). 1H NMR (DMSO-d6):
8.90 (d, J = 4.0 Hz, 1H), 8.89-8.86 (m, 1H), 8.69 (d, J = 8.4 Hz, 1H), 8.59 (dd, J = 9.0, 2.4 Hz,
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1H), 8.50 (d, J = 9.0 Hz, 1H), 4.50 (td, J = 9.8, 4.1 Hz, 1H), 3.66 (d, J = 5.7 Hz, 1H), 3.22 (dd, J
= 13.6 Hz, 2H), 3.06 (dd, J = 13.4, 10.3 Hz, 2H), 2.34 (d, J = 7.0 Hz, 2H), 2.09-1.65 (m, 2H).
13C

NMR (DMSO-d6): 171.9, 170.7, 170.1, 170.1, 145.3, 144.7, 144.5, 128.9, 128.2, 121.4, 52.9,

51.7, 48.6, 41.1, 31.5, 26.7. HMRS Calculated for C16H20N5O10S2 [M+H]+: m/z 506.0652 found
506.0643
1.4.3

Esterase-triggered lactone formation from 401 as monitored by HPLC.

Stock solution preparation: 401 was dissolved in DMSO to afford a 10-mM stock
solution. 5 mg of porcine esterase (18 unit/mg esterase from porcine liver, PLE, Aldrich, E3019)
was dissolved in 0.9 ml PBS to give a 100-unit/mL esterase stock solution.
401 (final Conc. 100 µM) was added to PBS (5 ml) with 2 unit/ml PLE at 37 °C. At
different time points, 200 µL reaction mixture was taken out and added to a centrifugation tube
containing 600 µL acetonitrile (ACN). After 5 min at -78 °C, the mixture was (14.5 × 1000 rpm,
3 min) centrifuged, and the supernatant was used as the sample for HPLC. The samples were
analyzed by HPLC (column: Waters C18 3.5 μM, 4.6×100 mm, injection loop volume: 20μL).
ACN and H2O (pH=4) were used as mobile phase.
1.4.4

Direct detection of GSSH by DNFB

Stock solution preparation: 401 was dissolved in DMSO to afford a 40-mM stock
solution and a 500 µM stock solution. DNFB was dissolved in DMSO to afford a 200-mM
solution.
Group 1: 2.5 µL of 40-mM 401 stock solution, 7.5 µL DMSO and 10 µL of DNFB stock
solution were added to 1 mL 10 unit/ml PLE solution. The mixture was incubated at 37 °C for 30
min.
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Group 2: 5 µL of 40-mM 401 stock solution, 5 µL DMSO and 10 µL DNFB stock
solution were added to 1 mL 10 unit/ml PLE solution. The mixture was incubated at 37 °C for 30
min.
Group 3: 10 µL of 40-mM 401 stock solution and 10 µL DNFB stock solution were
added to 1 mL 10 unit/ml PLE solution. The mixture was incubated at 37 °C for 30 min.
Group 4: 10 µL of 500-µM 401 stock solution and 10 µL DNFB stock solution were
added to 1 mL 1 unit/ml PLE solution. The mixture was incubated at 37 °C for 30 min.
400 µL of reaction mixture was taken out and added to a centrifuged tube containing 400
µL ACN at -78 °C for 5 min. The mixture (14.5 ×1000 rpm, 3 min) was centrifuged, and the
supernatant was used as the sample for HPLC. The samples were analyzed by HPLC (column:
Waters C18 3.5 μM, 4.6×100 mm, injection loop volume: 20μL). ACN and H 2O (pH=4) were
used as mobile phase.
1.4.5

Analysis of decomposed products from GSSH by LRMS

100 µM of 401 was incubated with 5 unit/ml PLE in a 10-mM ammonium bicarbonate
buffer contains 10% methanol at room temperature. At different time points, the reaction mixture
was directly injected and analyzed by mass spectrometer in ESI negative mode.
1.4.6

The MB method for detection of H2S release from 401

At specific time points, 200 µM of reaction solution was added into a 1.5 mL tube
containing 100 μL zinc acetate (1%, w/v). The mixture was centrifuged for 10 min (14.5 × 1000
rpm), followed by the removal of the supernatant. The precipitate was dissolved in 400 μL N,Ndimethyl-1,4-phenylenediaminesulfate (0.2% w/v in 20% H2SO4 solution) and 200 μL ferric
chloride (1% w/v in 0.2% H2SO4 solution). After 4 min incubation, the absorbance (at 740 nm)
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of the solution was measured. The concentration of H2S was determined by a standard curve of
Na2S·9H2O.
Group 1: 200 µM 401 was incubated in PBS.
Group 2: 200 µM 401 and 2 mM NAC were incubated in PBS.
Group 3: 200 µM 401 was incubated in PBS contains 10 unit/mL PLE.
Group 4: 200 µM 401 and 2 mM NAC were incubated in PBS contains 10 unit/mL PLE.
1.4.7

Quantification of the disulfide byproduct and GSH by LRMS

Group 1 (NAC trapping experiment): 200 µM 401 and 2 mM NAC were incubated in
PBS contains 10 unit/mL PLE for 30 min at 37 °C. The resulting solution was diluted 10 times
with a 10-mM ammonium bicarbonate buffer contains 10% methanol and 100 µM internal
standard before the analysis.
Group 2 (The disulfide byproduct standard): To the solution of GSH (31 mg, 0.1 mmol)
and NAC (163 mg, 1 mmol) in 4 ml H2O was added I2 (140 mg, 0.55 mmol). The mixture was
allowed to stir at room temperature for 30 min. The resulting solution was analyzed by MS to
make sure the GSH was fully reacted with NAC to give a 25-mM stock solution of the disulfide
byproduct. The stock solution was diluted to 20 µM in a 10-mM ammonium bicarbonate buffer
contains 10% methanol and 100 µM internal standard before the analysis.
Group 3 (GSH standard): 154 mg GSH was dissolved in 5 ml H2O to give a 100-mM
stock solution. The stock solution was diluted to 20 µM in a 10-mM ammonium bicarbonate
buffer contains 10% methanol and 100 µM internal standard before the analysis.
Internal standard: 100 µM of leu-enkephalin (Leu-Enk) was used as internal standard.
The analysis was performed in ESI negative mode.
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1.4.8

GAPDH activity measurement after different treatment

GAPDH (Sigma, G2267-1KU) was dissolved in PBS to afford a 2 mg/mL stock solution.
The solution was treated with 1 mM dithiothreitol (DTT) at 25 °C for 1 h. Then DTT was
removed using Amicon ultra 10K tube ×3 (UFC501096) and bio-spin column (Thermo, 7K
MWCO; 89882). PLE was dissolved in a GAPDH assay buffer 20 mM tris-HCl (pH 7.8) with
100 mM NaCl, BSA (0.1 mg/mL), and 2 mM NAD+ (nicotinamide adenine dinucleotide) to
afford a 10 unit/mL solution. Glyceraldehyde 3-phosphate was dissolved in the GAPDH assay
buffer to give a 6-mM solution. Lactone and 401 were dissolved in DMSO to afford a 10-mM
stock solution, respectively.
Group 1: 2 μL of GAPDH stock solution was added to PLE solution to make 2 μg/ml
GAPDH solution. 10 μL of DMSO was added to the mixture, and the mixture was further
incubated at 37 °C for 30 min.
Group 2: 2 μL of GAPDH stock solution was added to PLE solution to make 2 μg/ml
GAPDH solution. 10 μL of lactone stock solution was added to the mixture, and the mixture was
further incubated at 37 °C for 30 min.
Group 3: 2 μL of GAPDH stock solution was added to PLE solution to make 2 μg/ml
GAPDH solution. 10 μL of 401 stock solution was added to the mixture, and the mixture was
further incubated at 37 °C for 30 min.
Group 4: 2 μL of GAPDH stock solution was added to PLE solution to make 2 μg/ml
GAPDH solution. 5 μL of 401 stock solution and 5 μL DMSO was added to the mixture, and the
mixture was further incubated at 37 °C for 30 min.
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Group 5: 2 μL of GAPDH stock solution was added to PLE solution to make 2 μg/ml
GAPDH solution. 2.5 μL of 401 stock solution and 7.5 μL DMSO was added to the mixture, and
the mixture was further incubated at 37 °C for 30 min.
Each group was divided into two parts after the above treatments. For the first part,
GAPDH activity was determined. For the second part, the sample was incubated with 2 mM
DTT at rt for 2 h and then GAPDH activity was determined.
For GAPDH activity measurement, 100 μL aliquot from each group was mixed with 100
μL of 6 mM glyceraldehyde 3-phosphate solution. The formation of NADH was
spectrophotometrically monitored every two min at 340 nm at 37 °C.
1.4.9

Cytoprotective studies of BW-GP-401

Cytotoxicity of BW-GP-401: Cell viability was assessed by using Cell Counting Kit-8
(CCK-8, Dojindo, Japan). H9c2 cells were cultured in DMEM medium. The medium was
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. For cytotoxicity
assays, The H9c2 cells were seeded in a 96-well plate one day before the experiment. Various
concentrations of 401 were added to the cells. After incubation for 24 h at 37 °C in humidified
atmosphere with 5 % CO2, 10 μL of CCK-8 solution was added to each well, and the plate was
incubated for an additional 2 h at 37 °C. The 96-well plate was read by a microarray reader for
optical density at 450 nm; and the results were expressed as a percentage of the absorption of the
untreated control.
Measurement of H9c2 cell viability in H2O2-induced cell damage with various pretreatments: H9c2 cells were treated with various concentrations (50 µM, 100 µM and 150 µM)
of 401 with addition of 2 unit/mL of PLE for 1 h at 37 °C. Then, the cells were exposed to H 2O2
(450 µM) for another 3 h at 37 °C. The viability was evaluated by Cell Counting Kit-8 (CCK-8).
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For the control groups, no compound was added before the exposure of cells to H 2O2. 150 µM of
lactone, GSH and Na2S were also used in the same manner as the 401 group.

1.4.10 Synthesis of persulfide prodrugs BW-PP-501 to 504.

Figure 1.28 Synthesis of N-acetyl-S-(pyridin-2-ylthio)-L-cysteine (3).
Synthesis of N-acetyl-S-(pyridin-2-ylthio)-L-cysteine (3): To a stirred solution of 4,4ʹdithiodipyridine (2, 148 mg, 0.67 mmol) in THF (5 mL) was added N-acetyl-L-cysteine (1, 100
mg, 0.61 mmol) in THF (5 mL) at room temperature. The reaction mixture was stirred for 5 h at
room temperature. The solvent was evaporated under reduced pressure. The residue was purified
by silica gel column chromatography to yield the pure product (3, 100 mg, 60 %). 1H NMR
(CD3OD): δ 8.37 (d, J = 4.8 Hz, 1H), 7.77-7.76 (m, 2H), 7.21-7.17 (m, 1H), 4.66-4.63 (m, 1H),
3.32-3.27 (m, 2H), 3.14-3.09 (m, 1H), 1.94 (s, 3H). 13C NMR (CD3OD): δ 173.3, 160.7, 150.4,
139.1, 122.5, 121.4, 53.2, 41.5, 22.4; HRMS calcd for C10H12N2O3S2Na [M+Na]+ 295.0184,
found 295.0185.

Figure 1.29 Synthesis of BW-PP-501.
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Synthesis of S-((3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoyl)thio)-Nacetylcysteine (PP-501): BW-HP-101 was synthesized according to published procedure. 1 To a
solution of 3 (80 mg, 0.29 mmol) in chloroform (3 mL) was added dropwise BW-HP-101(81
mg, 0.29 mmol) in chloroform (1 mL). The mixture was stirred at room temperature for 2 h. The
solvent was evaporated under reduce pressure. The residue was purified by silica gel column
chromatography to yield the pure product (PP-501, 88 mg, 69 %). 1H NMR (CDCl3): δ = 7.46
(d, J = 6.8 Hz, 1H), 6.81 (s, 1H), 6.59 (s, 1H), 4.42-4.41 (m, 1H), 3.37 (dd, J = 14.2, 5.7 Hz, 1H),
3.30 (ABq, J = 16.0 Hz, 1H), 3.14 (ABq, J = 16.0 Hz, 1H), 2.83 (dd, J = 14.3, 4.6 Hz, 1H), 2.53
(s, 3H), 2.32 (s, 3H), 2.21 (s, 3H), 2.02 (s, 3H), 1.59 (s, 3H), 1.55 (s, 3H). 13C NMR (CDCl3): δ =
198.2, 172.6, 171.7, 170.1, 149.5, 138.0, 136.9, 132.7, 132.3, 123.3, 55.3, 52.1, 41.7, 40.2, 31.8,
31.6, 25.5, 22.6, 22.0, 20.3; HRMS calcd for C20H27NO6S2Na [M+Na]+ 464.1178, found
464.1194

Figure 1.30 Synthesis of 2-(propyldisulfanyl) pyridine (5).
Synthesis of 2-(propyldisulfanyl) pyridine (5): To a stirred solution of 4,4ʹdithiodipyridine (2, 159 mg, 0.72 mmol) and 25 µL acetic acid (AcOH) in MeOH (9 mL), was
added propanethiol (4, 50 mg, 0.65 mmol) in MeOH (2 mL) at room temperature. The reaction
mixture was stirred for 5 h at room temperature. The solvent was evaporated under reduced
pressure. The residue was purified by silica gel column chromatography to yield the pure product
(5, 90 mg, 81 %). 1H NMR (CDCl3): δ 8.39 (s, 1H), 7.71-7.58 (m, 2H), 7.01 (m, 1H), 2.75-2.70
(m, 2H), 1.70-1.66 (m 2H), 0.98-0.92 (m, 3H). 13C NMR (CDCl3): δ 160.6, 149.4, 136.9, 120.4,
119.4, 40.8, 22.2, 13.0; HRMS calcd for C8H12NS2Na [M+H]+ 186.0411, found 186.0408.
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Figure 1.31 Synthesis of BW-PP-502.
Synthesis of 3,5-dimethyl-2-(2-methyl-4-oxo-4-(propyldisulfanyl)butan-2-yl)phenyl
acetate (PP-502): To a solution of 5 (80 mg, 0.43 mmol) in chloroform (3 mL) was added
dropwise BW-HP-101 ( 121 mg, 0.43 mmol) in chloroform (1 mL). The mixture was stirred at
room temperature for 2 h. The solvent was evaporated under reduce pressure. The residue was
purified by silica gel column chromatography to yield the pure product (PP-502, 93 mg, 61
%).1H NMR (CDCl3): δ = 6.80 (s, 1H), 6.61 (s, 1H), 3.18 (s, 2H), 2.55-2.51 (m, 5H), 2.32 (s,
3H), 2.22 (s, 3H), 1.58 (s, 6H), 1.50 (dd, J = 14.8, 7.6 Hz, 2H), 0.95 (t, J = 7.6 Hz, 3H). 13C
NMR (CDCl3): δ = 196.0, 169.9, 149.6, 138.0, 136.6, 132.7, 132.6, 123.2, 54.8, 40.7, 40.1, 31.6,
25.5, 22.3, 22.0, 20.3, 13.1; HRMS calcd for C18H26O3S2Na [M+Na]+ 377.1221, found 377.1213.

Figure 1.32 Synthesis of 2-(benzyldisulfanyl) pyridine (7).
Synthesis of 2-(benzyldisulfanyl) pyridine (7): To a stirred solution of 4,4ʹdithiodipyridine (2, 155 mg, 0.70 mmol) in MeOH (10 mL) was added benzyl mercaptan (4, 80
mg, 0.59 mmol) in MeOH (5 mL) at room temperature. The reaction mixture was stirred for 5 h
at room temperature. The solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography to yield the pure product (7, 119 mg, 88 %). 1H
NMR (CDCl3): δ 8.45 (m, 1H), 7.53 (m, 2H), 7.31-7.23 (m, 5H), 7.06-7.03 (m, 1H), 4.04 (s, 2H).
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13C

NMR (CDCl3): δ 160.1, 149.5, 136.8, 136.6, 129.4, 128.6, 127.7, 120.5, 119.5, 43.7; HRMS

calcd for C12H11NS2Na [M+Na]+ 256.0231, found 256.0228.

Figure 1.33 Synthesis of BW-PP-503.

Synthesis of 2-(4-(benzyldisulfanyl)-2-methyl-4-oxobutan-2-yl)-3,5-dimethylphenyl
acetate (PP-503): To a solution of 7 (85 mg, 0.36 mmol) in chloroform (3 mL) was added
dropwise BW-HP-101 (100 mg, 0.36 mmol) in chloroform (1 mL). The mixture was stirred at
room temperature for 2 h. The solvent was evaporated under reduce pressure. The residue was
purified by silica gel column chromatography to yield the pure product (HP-503, 90 mg, 62 %).
1H

NMR (CDCl3): δ = 7.30-7.25 (m, 5H), 6.82 (s, 1H), 6.62 (s, 1H), 3.80 (s, 2H), 3.16 (s, 2H),

2.53 (s, 3H), 2.31 (s, 4H), 2.23 (s, 3H), 1.55 (s, 6H). 13C NMR (CDCl3): δ = 195.4, 169.7, 149.3,
137.8, 136.5, 136.2, 132.7, 132.5, 129.3, 128.4, 127.6, 123.1, 54.8, 42.7, 39.8, 31.3, 25.4, 21.9,
20.2; HRMS calcd for C22H26O3S2Na [M+Na]+ 425.1221, found 425.1208.

Figure 1.34 Synthesis of 2-((4-(trifluoromethyl)benzyl)disulfanyl) pyridine (9).
Synthesis of 2-((4-(trifluoromethyl)benzyl)disulfanyl) pyridine (9): To a stirred solution of
4,4ʹ-dithiodipyridine (2, 137 mg, 0.62 mmol) in MeOH (10 mL) was added 4trifluoromethylbenzyl mercaptan (8, 100 mg, 0.52 mmol) in MeOH (5 mL) at room temperature.
The reaction mixture was stirred for 5 h at room temperature. The solvent was evaporated under
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reduced pressure. The residue was purified by silica gel column chromatography to yield the
pure product (9, 120 mg, 76 %). 1H NMR (CDCl3): δ 8.41-8.39 (m, 1H), 7.46-7.36 (m, 6H),
7.03-7.00 (m, 1H), 4.03 (s, 2H). 13C NMR (CDCl3): δ 159.4, 149.6, 140.8, 136.8, 129.8, 125.5
(q, J = 4 Hz), 122.7, 120.8, 119.8, 43.0; HRMS calcd for C13H10NS2F3Na [M+Na]+ 324.0097,
found 324.0097.

Figure 1.35 Synthesis of BW-PP-504.
Synthesis of 3,5-dimethyl-2-(2-methyl-4-oxo-4-((4(trifluoromethyl)benzyl)disulfanyl)butan-2-yl)phenyl acetate (PP-504): To a solution of 9 (60
mg, 0.20 mmol) in chloroform (3 mL) was added dropwise BW-HP-101 (66 mg, 0.23 mmol) in
chloroform (1 mL). The mixture was stirred at room temperature for 2 h. The solvent was
evaporated under reduce pressure. The residue was purified by silica gel column chromatography
to yield the pure product (PP-504, 50 mg, 53 %).1H NMR (CDCl3): δ = 7.53 (d, J = 8.0 Hz, 2H),
7.31 (d, J = 8.0 Hz, 2H), 6.80 (s, 1H), 6.60 (s, 1H), 3.79 (s, 2H), 3.13 (s, 2H), 2.50 (s, 3H), 2.29
(s, 3H), 2.21 (s, 3H), 1.52 (s, 6H). 13C NMR (CDCl3): δ = 194.8, 169.7, 149.3, 140.4, 137.8,
136.6, 132.5, 129.6, 125.3, 123.1, 54.9, 41.8, 39.9, 31.3, 25.3, 21.8, 20.2; HRMS calcd for
C23H25F3O3S2Na [M+ Na]+ 493.1095, found 493.1083.
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1.4.11 Synthesis of the persulfide trapped products

Figure 1.36 Synthesis of N-acetyl-S-((2,4-dinitrophenyl)thio)-L-cysteine (13).

Synthesis of N-acetyl-S-((2,4-dinitrophenyl)thio)-L-cysteine (13): To a stirred solution of
2,4-dinitrobenzenesulfenyl chloride (12, 115 mg, 0.49 mmol) in DCM (4 mL) was added Nacetyl-L-cysteine (1, 80 mg, 0.49 mmol) in DMF (1 mL) at room temperature. The reaction
mixture was stirred for 6 h at room temperature. The solvent was evaporated under reduced
pressure. The residue was purified by silica gel column chromatography to yield the pure product
(13, 102 mg, 57 %). 1H NMR (MeOD): δ 8.97 (s, 1H), 8.55-8.52 (m, 2H), 4.62-4.59 (m, 1H),
3.35-3.34 (m,1H), 3.21-3.16 (m, 1H), 2.02 (s, 3H). 13C NMR (MeOD): δ 173.4, 147.1, 146.5,
130.1, 128.7, 122.3, 41.8, 22.7; HRMS calcd for C11H11N3O7S2Na [M+Na]+ 383.9931, found
383.9936.

Figure 1.37 Synthesis of 1-(2,4-dinitrophenyl)-2-propyldisulfane (14).

Synthesis of 1-(2,4-dinitrophenyl)-2-propyldisulfane (14): To a stirred solution of 2,4dinitrobenzenesulfenyl chloride (12, 100 mg, 0.42 mmol) in AcOH (4 mL) was added

42
propanethiol (4, 32 mg, 0.42 mmol) in AcOH (1 mL) at room temperature. The reaction mixture
was stirred for 6 h at room temperature. The solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to yield the pure product (14, 97 mg,
84 %). 1H NMR (CDCl3): δ 9.09 (d, J = 2.4 Hz, 1H), 8.54-8.45 (m, 2H), 2.76 (t, J = 7.2 Hz, 2H),
1.74-1.69 (m, 2H), 1.02 (t, J = 7.2 Hz, 3H). 13C NMR (CDCl3): δ 146.9, 145.5, 145.1, 128.8,
127.4, 121.7, 40.6, 22.5, 13.2; HRMS calcd for C9H10N2O4S2Na [M+Na]+ 296.9980, found
296.9978.

Figure 1.38 Synthesis of 1-benzyl-2-(2,4-dinitrophenyl) disulfane (15).
Synthesis of 1-benzyl-2-(2,4-dinitrophenyl) disulfane (15): To a stirred solution of 2,4dinitrobenzenesulfenyl chloride (12, 137 mg, 0.58 mmol) in AcOH (3 mL) was added 4-benzyl
mercaptan (6, 72 mg, 0.58 mmol) in AcOH (2 mL) at room temperature. The reaction mixture
was stirred for 6 h at room temperature. The solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to yield the pure product (15, 102 mg,
55 %). 1H NMR (CDCl3): δ 8.98 (s, 1H), 8.14-8.03 (m, 2H), 7.24-7.16 (m, 4H), 4.00 (s, 2H). 13C
NMR (CDCl3): δ 146.1, 145.2, 144.9, 135.5, 129.2, 128.8, 128.0, 126.5, 121.1, 43.5; HRMS
calcd for C13H10N2O4S2 [M+Na]+ 344.9980, found 344.9987.
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Figure 1.39 Synthesis of 1-(2,4-dinitrophenyl)-2-(4-(trifluoromethyl)benzyl) disulfane
(16).

Synthesis of 1-(2,4-dinitrophenyl)-2-(4-(trifluoromethyl)benzyl) disulfane (16): To a
stirred solution of 2,4-dinitrobenzenesulfenyl chloride (12, 137 mg, 0.58 mmol) in AcOH (3 mL)
was added 4-trifluoromethylbenzyl mercaptan (8, 112 mg, 0.58 mmol) in AcOH (2 mL) at room
temperature. The reaction mixture was stirred for 6 h at room temperature. The solvent was
evaporated under reduced pressure. The residue was purified by silica gel column
chromatography to yield the pure product (16, 120 mg, 53 %). 1H NMR (CDCl3): δ 8.98 (d, J =
2.0 Hz, 1H), 8.19-8.05 (m, 2H), 7.44-7.33 (m, 4H), 4.03 (s, 2H). 13C NMR (CDCl3): δ 145.5,
145.4, 145.2, 139.7, 129.7, 128.8, 126.8, 125.7 (q, J = 4 Hz), 42.7; HRMS calcd for
C14H9F3N2O4S2Na [M+Na]+ 412.9854, found 412.9866.
1.4.12 Quantification of persulfide release from 501 to 504
Stock solution preparation: Various persulfide prodrugs were dissolved in DMSO to
afford 10-mM stock solutions. DNFB was dissolved in DMSO to afford a 400 mM stock
solution.
For each prodrug, 2.5 L of 10 mM prodrug stock solution and 25 L of 400 mM DNFB
stock solution were added to 972.5 L PBS containing 10 units/mL PLE solution. The final
concentrations for prodrug and DNFB were 25 µM and 10 mM respectively. The mixture was
incubated at 37 C for 30 min. 300 L reaction mixture was taken out and added into a vial
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containing 600 L acetonitrile (ACN). The mixture was incubated in an acetone dry ice bath (-78
°C) for 5 min and centrifuged for 10 min (14.5 × 1000 rpm). The supernatant was subjected for
HPLC analysis (column: Waters C18 3.5 μM, 4.6×100 mm). The mobile phase was acetonitrile
(ACN)/H2O (pH=4.0). Eluent conditions (% of ACN): 10% to 85%, 0 to 15 min; 85%, 15 to 20
min; 85% to 10%, 20 to 25 min.
The formation of R-SS-DNFB was calculated based on the corresponding R-SS-DNFB
standard curve.
1.4.13 Persulfide stability studies
Stock solution preparation: Various persulfide prodrugs were dissolved in DMSO to
afford 10 mM stock solutions. DNFB was dissolved in DMSO to afford a 130-mM stock
solution.
To a 20 mL vial was added 4 mL of PBS containing 20 units/mL PLE and 10 L 10 mM
prodrug stock solution. At different time points (10s, 20s, 30s, 40s, 50s, 60s), 300 L reaction
mixture was taken out and added to a 1.5 mL tube containing 25 L of 130 mM DNFB stock
solution (the final DNFB concentration is 10 mM). The mixture was further incubated at 37 °C
for 30 min. Then 575 L ACN was added to the reaction mixture. Then the mixture was
centrifuged for 4 min (14.5 × 1000 rpm). The supernatant was analyzed by HPLC. The mobile
phase was acetonitrile (ACN)/H2O (pH=4.0) with ratios defined in the table below.
Table 1.3 The HPLC eluent conditions for monitoring the persulfide concentration.
Persulfide prodrugs Eluent conditions (% of ACN)
PP-501

30% to 90%, 0 to 30 min;
90% to 95%, 30 to 35 min;
95%, 35 to 50 min;
95% to 30%, 50 to 60 min
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PP-502

30%, 0 to 5 min;
30% to 70%, 5 to 30 min;
70% to 95%, 30 to 35 min;
95%, 35 to 50 min;
95% to 30%, 50 to 60 min

PP-503

30%, 0 to 5 min;
30% to 70%, 5 to 30 min;
70% to 95%, 30 to 35 min;
95%, 35 to 50 min;
95% to 30%, 50 to 60 min

PP-504

30%, 0 to 5 min;
30% to 70%, 5 to 30 min;
70% to 95%, 30 to 35 min;
95%, 35 to 50 min;
95% to 30%, 50 to 60 min

1.4.14 N-CysSSH degradation studies
H2S detection from persulfide degradation: H2S generation due to N-CysSSH
degradation was detected by the methylene blue method. PP-501 was dissolved in DMSO to
afford 5 mM stock solution. To 1 mL PBS with 10 units/mL PLE or without PLE was added 20
µL 5 mM HP-501 stock (the final PP-501 concentration was 100 µM). The mixture was then
incubated at 37 °C for 10 min. 200 μL of reaction solution was taken into a 1.5 mL tube
containing 200 μL zinc acetate (1% in H2O, w/v). Then the tube was centrifuged for 10 min
(14.5 × 1000 rpm). The supernatant was removed. Then 100 μL N,N-dimethyl-1,4phenylenediaminesulfate (0.2% w/v in 20% H2SO4 solution) and 100 μL ferric chloride (1% w/v
in 0.2% H2SO4 solution) were added to the tube. After 6 min, the absorbance (at 740 nm) of the
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resulting solution was measured. H2S concentration was calculated based on a calibration curve
of Na2S·9H2O.
H2Sn detection from persulfide degradation: H2Sn generation due to N-CysSSH
degradation was detected by a fluorescent probe, DSP-3.2 PP-501 was dissolved in DMSO to
afford a 5 mM stock solution. Na2S2 was dissolved in PBS to afford 5-mM stock solution. DSP-3
was dissolved in CAN to prepare a 0.5-mM stock solution. Cetrimonium bromide (CTAB) was
dissolved in ethanol to prepare a 5-mM stock solution.
To 5 mL PBS with 10 units/mL PLE was added 100 µL 5 mM PP-501 stock (the final
PP-501 concentration was 100 µM). The mixture was incubated at 37 °C for 10 min to allow for
the release and degradation of N-CysSSH. Then 25 μL of 5-mM CTAB stock and 200 μL 0.5mM DSP-3 stock were added to the mixture. The mixture was incubated at room temperature for
5 min. Then fluorescence intensity at 515 nm was recorded with excitation at 490 nm. PBS
containing 10 units/mL PLE but without PP-501 was used to record background fluorescence
intensity. Na2S2 was used as positive control.
N-CysSSH degradation products studied by MS: PP-501 was dissolved in DMSO to
afford a 5-mM stock solution. To 5 mL of 10 mM NH4HCO3 solution containing 10 units/ml
PLE was added 100 μL the 5-mM PP-501 stock solution. The final concentration for PP-501
was 100 μM. The mixture was incubated at 37 °C for 10 min. After that, the mixture was
subjected to MS analysis using the negative mode. A 10-mM NH4HCO3 solution containing 10
units/ml PLE but without PP-501 was used for MS background analysis.
1.4.15 Kinetics studies of PP-501 by monitoring lactone formation
PP-501 (finial Conc. 200 M) was added to PBS (5 mL) with 1 unit/mL esterase at 37
C. 300 L reaction mixture was taken out at different time point and added into a vial
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containing 600 L ACN. The mixture was incubated in an acetone dry ice bath (-78 °C) for 5
min and centrifuged for 10 min (14.5 × 1000 rp). The supernatant (injection volume of 20 L)
was subjected for HPLC analysis (column: Waters C18 3.5 μM, 4.6×100 mm). The mobile phase
was acetonitrile (ACN)/H2O (pH=4.0). The gradient elution method is described below:
0 to 20 min: 45% to 65% ACN; 20 to 25 min, 65 to 95% ACN; 25 to 50 min, 95%
ACN; 50 to 60 min, 95% to 45% CAN. Flow rate: 0.8 mL/min.
The retention time of lactone is 14.9  0.2 min.
1.4.16 Cytoprotective studies of persulfide prodrugs
H9c2 cells were treated with 100 µM of various prodrugs with addition of 1 unit/mL of
PLE for 1 h at 37 °C in humidified atmosphere with 5 % CO2. Then, the cells were exposed to
H2O2 (500 µM) for another 4 h at 37 °C. After that, the viability was evaluated by Cell Counting
Kit-8 (CCK-8).

2

STUDIES OF CO- INDEPENDENT REACTIVITIES FROM RUTHENIUM-BASED
CO-RELEASING MOLECULES

2.1

Introduction

(This chapter is mainly based on my publications: Chem. Commun. 2020, 56 (14), 21902193, Anal. Chem. 2020, under revision)
As an endogenously produced gaseous molecule, carbon monoxide (CO) has been well
demonstrated by many studies to possess signaling roles in mammals.47 More importantly, the
therapeutic effects of CO have been validated extensively in various disease models, including
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colitis, inflammatory sepsis, drug-induced organ toxicity and others.48-52 Earlier studies including
some human clinical trials employed inhalation form of CO.48, 53 However, limitations such as
the need for a special inhalation device, risk to patients and healthcare workers, and difficulties
in controlling dosage48, 54 led many to search for delivery forms that are more compatible for
wide-spread use.48, 50, 55-57 Along this line, Motterlini and Mann pioneered the use of metalimmobilized carbonyls as CO-releasing molecules (CO-RMs)48, 58-61 with many others also
reporting very interesting CORMs.62-65 Among all the metal-based CORMs, two rutheniumbased, CORM-2 and CORM-3, are probably the most widely used as CO donors for a large
number of studies. A quick PubMed search of “CORM-2 OR CORM-3” led to about 500 hits,
demonstrating the broad impact of these two CO-RMs. Later efforts in developing CO donors
include photo-sensitive organic CO-RMs56, 66-72 and organic CO prodrugs (Figure 1).73-76

Figure 2.1 Structures of representative CO donors.

Both for mechanistic studies and pharmaceutical development, there is a need for a
thorough understanding of the pharmacokinetic profiles of each delivery form and their
correlation with pharmacodynamics in a given indication. Therefore, tools for real-time and
highly accurate measurement of CO levels in circulation and at the cellular and tissue levels are
in great need. Currently, oximeters are the most commonly used tools for determining carboxy
hemoglobin (COHb) levels as a surrogate indicator of CO exposures in the systemic
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circulation.77 There have been continuous efforts in developing molecular fluorescent probes and
sensors for CO for cellular and tissue-based CO measurements and imaging work. After Chang’s
palladium-based fluorescent probe for CO (COP-1),78 there have been extensive efforts along a
similar line, leading to several analogous CO probes (Figure 2.2).79-82 He and coworkers also
reported a genetically encoded fluorescent protein as CO sensor based on the binding affinity of
CO to the iron center on a heme cofactor.83 These probes all rely on the affinity of CO for a
transition metal. Recently, there are exciting reports of metal-free fluorescent CO probes, which
suggest the ability of CO to reduce a nitro group on an aromatic core, leading to fluorescent turnon (Figure 2.2).84-86 Such feasibility was demonstrated with two ruthenium-based CO-RMs,
CORM-2 and CORM-3, as the source of CO.58, 61 We were interested in borrowing from this
exciting strategy for designing CO probes for pharmacokinetic studies. As a first step, we
confirmed the reported results using COFP, and thus the reproducibility of the literature results.
However, upon further examination of these probes using different delivery forms of CO, it was
found that the fluorescent probe only worked when the CO donors were ruthenium-based. As
such, we examined the general utility of the published nitro reduction-based CO probes, and we
concluded that these CO probes only sense ruthenium-based CO donors, CORM-2 and CORM3, not CO in general. Additionally, we found that CORM-3 is capable of reducing an aryl nitro
group to an amino group under near-physiological conditions, and such effects cannot be
achieved by iCORM or CO from other sources including CO gas. Taken together, these results
also firmly presented a CO-independent reactivity of ruthenium-based CO-RMs, CORM-2,3.
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Figure 2.2 Structures of representative fluorescent CO probes for CO detection and in
vitro imaging.
As shown in Figure 2.1, CORM-2 and CORM-3 are both ruthenium-carbonyl
complexes and have been reported to transfer CO spontaneously under physiological
conditions.48, 60 In a typical study using a metal-based CO-RM, the depleted CO-RM after release
CO (iCO-RM) is used as the negative control. An ideal CO donor should not have COindependent effects. If it does, then the iCO-RM control should duplicate such CO-independent
effects in order to assess the true effect of CO. However, several recent studies indicated that
some of the reported biological effects of metal-based CORMs such as CORM-2 and CORM-3
cannot be attributed to the ability for them to donate CO.65, 87-100 Additional studies reported
some unique chemical reactivities of ruthenium-based CO-RMs. For example, Poole and
coworkers used NMR to determine the Kd between CORM-3 and biological thiol species
(cysteine and glutathione) to be about 5 M.87 Heinemann and coworkers reported the COindependent functions on K+ channels by CORM-2.98 Nielsen described that the widely studied
effect of CORM-2 against snake venom was through a CO-independent mechanism.90 Stahl and
colleagues described the ability for CORM-2 to consume molecular oxygen in solution.92 These
results, coupled with our finding based on the reactivity of CORM-2,3 on nitro-based CO probe,
show a number of effects from ruthenium-based CO-RMs are CO-independent.
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Given the wide-spread use, the large number of reports using CORM-2,3 as CO donors,
and the telltale signs of their chemical reactivity under physiological conditions, we decided to
further systemically study the CO-independent reactivity of these two ruthenium-based CORMs
with reagents commonly used in cellular assays such as resazurin, tetrazolium salts, nitrite and
azide-based H2S probes. It was found that both CORM-2 and CORM-3 have CO-independent
reactivities toward these bioassay reagents. The implications of these findings are far-reaching.
However, how such findings would affect the interpretations of results from each specific study,
which has used CORM-2 or CORM-3, is beyond the scope of this study, and is best left to
experts who are most familiar with the interpretation of the biological problems examined in
each study.
2.2

Results and discussions
2.2.1

Responses of COFP upon treatment with various CO sources

Figure 2.3 Responses of COFP upon treatment with CO-103. A) CO release from CO103; B) Fluorescence spectra of COFP (10 M) upon treatment with CO-103 (100 M) over 2 h
in DMSO/PBS (pH = 7.4) 5:1 at 37 C (ex= 440 nm, slit widths: Wex = Wem = 10 nm); C)
Fluorescence spectra of CP-103 formation after the incubation with COFP in DMSO/PBS (pH =
7.4) 5:1 at 37 C (ex = 373 nm, slit widths: Wex = Wem = 5 nm).
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Following the exciting work of Dhara et al., we were interested in examining how well
COFP would allow us to determine the quantity of CO release from different delivery forms. We
first chose BW-CO-103 (CO-103), which belongs to the class of metal-free organic CO
prodrugs widely validated in multiple pharmacological animal models including colitis, liver
injury, systemic inflammation, and kidney ischemia reperfusion injury.73, 74, 101 An added
advantage of using CO-103 for the initial study is the prodrug’s ability to concomitantly produce
a fluorescent product, CP-103, together with CO release (Figure 2.3A).73 This would give a way
to cross-validate the results from the fluorescent probe in a quantitative fashion in solution, in
cell culture, and possibly in animal models. With these design ideas in mind, we first explored
the ability for the 1,8-naphthalimide-based probe COFP to sense the CO produced from CO103. Much to our dismay, no fluorescent turn-on was observed at around 522 nm, which is
expected within 2 h from the fluorescent turn-on CO probe (Figure 2.3B). In contrast, we
observed a significant fluorescent intensity increase due to the production of CP-103 after 2 h of
incubation, suggesting CO production (Figure 2.3C).
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Figure 2.4 Fluorescence spectra of COP-1 (1 M) upon treatment with CO-103 (100
M) over 2 h in DMSO/PBS (pH = 7.4) 5:1 at 37 C (ex = 475 nm, slit widths: Wex = 5 nm, Wem
= 3 nm).

Figure 2.5 Fluorescence spectra of CP-103 formation during incubation with COP-1 (1

M) in DMSO/PBS (pH = 7.4) 5:1 at 37 C (ex = 373 nm, slit widths: Wex = Wem = 5 nm).

To further examine the generation of CO from CO-103, 1 M COP-1 was incubated with
CO-103 under the same conditions. A fluorescent signal increase at 507 nm was observed from
COP-1 after 2 h (Figure 2.4) along with formation of CP-103 (Figure 2.5). Such results also
confirmed CO production. As additional positive controls, we also examined the probe’s ability
to detect CO released from CORM-2 and CORM-3 as reported in the literature (Figure 2.6).84
As expected, it was reassuring that we were able to completely reproduce the solution studies of
COFP as reported in the literature.
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Figure 2.6 Fluorescent spectra of COFP (10 M) upon incubation with A) CORM-2
(100 M) and B) CORM-3 (100 M) in PBS (pH = 7.4, 4% DMSO) at 37 C. (ex= 440 nm, slit
widths: Wex = Wem = 10 nm)
As additional controls, we also bubbled CO gas through the probe solution and did not
see any fluorescent changes (Figure 2.7A). We further examined the existence of CO in solution
using Chang’s probe, COP-1,78 and observed strong fluorescent intensity changes at 507 nm
(Figure 2.7B). Then, it became clear that COFP did not sense CO delivered in the form of CO
gas or from CO-103.

Figure 2.7 Fluorescence spectra of A) COFP (10 M) and B) COP-1 (1 M) upon
treatment with CO gas in PBS (2% DMSO) at 37 C for 1 h. (COFP: ex= 440 nm, slit widths:
Wex = 15 nm, Wem = 10 nm; COP-1: ex = 475 nm, slit widths: Wex = 5 nm, Wem = 3 nm).
At this time, it is important to analyze CO’s chemistry in the context of CO sensing and
CO’s reactivity in vivo. CO is a Lewis base with strong affinity for transition metals.102-104
However, it is a consensus in the CO field that in the body, CO undergoes minimal metabolism,
despite the presence of a large number of organic molecules with reducing ability and enzymes
capable of catalyzing redox reactions.105, 106 Administered CO largely eliminates through
exhalation. There is a large body of literature along this line from studying the physiology and
pharmacokinetic properties of CO and in the smokers’ population.107-109 All such reports suggest
that CO is very inert. A further search of the chemistry literature indicates that CO is also inert
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toward an arylnitro group under normal physiological conditions, as one would expect. However,
there are ample precedents that CO is effective in reducing an arylnitro group in the presence of
catalytic amounts of transition metal complexes such as that of Au, Ru, Se, and Rh among
others.110-114 Coincidentally, CORM-2 and CORM-3 were the only ones examined as CO
sources in the reported work.84-86 These nitro reduction-based CO probes were not tested on CO
gas or other metal-free CO donors.
A)

B)

Figure 2.8 Fluorescent spectra of COFP (10 M) upon incubation with A) CORM-A1
(100 M) and B) CORM-401 (100 M) over 60 min in PBS (pH = 7.4, 4% DMSO) at 37 C.
(ex= 440 nm, slit widths: Wex = Wem = 10 nm)
In order to further examine the scope of the probe’s ability to detect CO from other CORMs, we also conducted studies using a boron-based CO donor CORM-A1 and a manganesebased CORM-401 with reported release half-life being 21 min and less than 4 min
respectively.59, 115 Specifically, we incubated 10 M COFP with 100 M CORM-A1 and
CORM-401 in PBS at 37 C. However, we did not observe any fluorescent intensity changes
from these CO-RMs within 60 min (Figure 2.8). As positive controls, CORM-A1 and CORM401 were also incubated with COP-1 under the same conditions; and fluorescent signal increases
at 507 nm from COP-1 were observed after 60 min (Figure 2.9).
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A)

B)

Figure 2.9 Fluorescent spectra of COP-1 (1 M) upon incubation with A) CORM-A1
(100 M) and B) CORM-401 (100 M) over 60 min in PBS (pH = 7.4, 4% DMSO) at 37 C.
(ex = 475 nm, slit widths: Wex = 5 nm, Wem = 3 nm).
2.2.2
A)

Responses of LysoFP-NO2 and NIR-CO upon treatment with CO gas
B)

Figure 2.10 Fluorescent spectra of LysoFP-NO2 (10 M) upon incubation with A)
CORM-3 (100 M) and B) CO gas in PBS (pH = 7.4, 4% DMSO) at 37 C. (ex= 440 nm, slit
widths: Wex = Wem = 10 nm)
As further assessment, we also studied the other two published nitro-based CO probes,
LysoFP-NO285 and NIR-CO86 (Figure 2.2), for their response toward CO from ruthenium-based
CO-RMs and pure CO gas. As shown in Figure 2.10, CO gas did not turn on LysoFP-NO2 after
1 h incubation at 37 °C. However, consistent with the original report, we did observe fluorescent
signal increase from LysoFP-NO2 upon the incubation with CORM-3 (Figure 2.10). Indeed, the
results are consistent with what the authors of the LysoFP-NO2 probe claim i.e. LysoFP-NO2 is
a CORM-3 probe. Next, NIR-CO was assessed by using various concentrations of CORM-2
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following the reported procedure.86 After incubation for 15 min at room temperature, it was
found the absorption peak of NIR-CO at 400 nm decreased in a concentration-dependent fashion
while the absorption peak at around 625 nm increased concomitantly, indicating the formation of
the reduced amino product (Figure 2.11). In contrast, no spectroscopic change was observed for
NIR-CO after treatment with pure CO gas (Figure 2.11). Such results indicate that NIR-CO
does not sense CO delivered in the gas form and is not a general CO probe. Since the biology
experiments are beyond the scope of the chemistry question on hand, we did not assess the
ability for NIR-CO to sense CO in cell culture and in zebrafish as reported in the original study.

Figure 2.11 Absorption spectra of NIR-CO (10 M) upon the treatment with CO gas and
various concentrations of CORM-2 in HEPES buffer (5 mM, pH = 7.4, 30% DMSO) at r.t. for
15 min.

2.2.3

Reduction of an arylnitro group by CORM-3
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Figure 2.12 HPLC of the PNB/CORM-3 reaction.
To further investigate the ability for ruthenium-based CO-RMs to reduce an arylnitro
group, we also studied a p-nitrobenzamide compound, PNB (Figure 2.12), as a substrate. The
HPLC results showed that PNB was completely consumed within 30 min after CORM-3 addition
(Figure 2.12), accompanied by the formation of a new peak corresponding to the reduced
product, p-aminobenzamide (PAB). We also performed LC-MS experiments as a secondary
verification of the formation of PAB (Figure 2.13). After confirmation of CORM-3’s ability to
reduce PNB to PAB, CO gas was used to conduct the same experiments. It was found that
bubbling CO gas into a PNB solution for 2 h at 37 °C did not lead to either changes to the PNB
peak nor formation of PAB as studied using HPLC and LC-MS. Such results again indicate that
CO alone does not reduce an arylnitro group in the absence of a metal complex such as CORM-3
(Figure 2.13). As such, it is reasonable for us to conclude that CO alone does not reduce an
arylnitro group to turn on the fluorescence of the probes in question. Likely, the ruthenium core
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in CORM-2 or CORM-3 played a catalytic role in enabling the reduction of the nitro group by
CO.

A)

C)

B)

D)

Figure 2.13 LC/MS analysis of the HPLC sample: (A) Before addition of CORM-3, PNB
peak at 5.9 min with m/z=223.3 [M+H]+; (B) PAB reference peak at 4.8 min with m/z=193.0
[M+H]+; (C) Reaction mixture with CORM-3 showed PAB peak at 4.8 min with m/z=193.4
[M+H]+; (D) Bubbling PNB with CO showed only PNB peak at 5.9 min with m/z=223.2
[M+H]+
2.2.4

Reactivities of inactive CORMs toward COFP

Then we looked into whether the ruthenium core without CO would turn on COFP by
itself. Complex D was obtained without carbonyl groups attached to the ruthenium core (Figure

60
2.14B).116 Upon incubation of Complex D with COFP in PBS at 37 C, no fluorescent increase
was observed within 1 h (Figure 2.15). Such results suggest that the ruthenium core alone cannot
reduce the aryl nitro group. Then, it is reasonable to assume that the reducing ability of CORM2 and CORM-3 might come from the ruthenium-carbonyl complex.

Figure 2.14 The reactivities of CORM-2 and its analogs toward COFP. A) reaction
between CORM-2 and DMSO; B) chemical structure of complex D; C) fluorescence intensity
changes from COFP (10 M) upon treatment with (1) CORM-2 and (2) reaction products from
mixing CORM-2 and DMSO in PBS (pH = 7.4, 4% DMSO) at 37 C. (ex = 440 nm, em= 522
nm, slit widths: Wex = Wem = 10 nm)

Figure 2.15 Fluorescent spectra of COFP (10 M) upon incubation with complex D (100
M) for 60 min in PBS (pH = 7.4, 4% DMSO) at 37 C. (ex = 440 nm, slit widths: Wex = Wem =
10 nm)
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Previous NMR studies showed that one CORM-2 molecule can dissociate into tricarbonyl (Complex A) and di-carbonyl monomers (Complex B and C) by DMSO during the
solubilization process (Figure 2.14A).61 One carbonyl group can be displaced by DMSO to form
complex B or C with loss of a CO molecule. With this in mind, we were interested in comparing
the reducing ability of CORM-2 and its products from ligand substitution with DMSO with the
aim of examining if the ruthenium-coordinated CO is involved in the reduction mechanism.
Following a reported procedure, CORM-2 was dissolved in DMSO and incubated at room
temperature for 30 min. Gas bubbles from the solution were observed during the incubation,
which is consistent with previously published results, and indicate the transformation from
CORM-2 to Complexes B and C with the release of one CO molecule. The resulting solution
was further examined with COFP by monitoring the fluorescence signal (Figure 2.16), which
should be indicative of the reduction reaction. As shown in Figure 2.14C, both of the reduction
rate and final fluorescence intensity were lower when the DMSO-CORM-2 solution was used
when compared to the fresh CORM-2 treated control group. Such results were presumably due
to the loss of CO from the ruthenium complex prior to exposure to COFP.

Figure 2.16 Fluorescent spectral changes of COFP (10 M) upon incubation with
reaction products between CORM-2 and DMSO (100 M) in PBS (pH = 7.4, 4% DMSO) at 37
C. (ex = 440 nm, slit widths: Wex = Wem = 10 nm)
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Additionally, we also examined the responses of COFP upon treatment with inactive
CORM-3 (iCORM-3). According to previous infrared spectroscopy studies, iCORM-3 is a
dicarbonyl species formed by loss of one CO molecule from CORM-3.58 Similar to the case of
CORM-2 and DMSO-CORM-2 solution, the reduction rate and final fluorescence intensity were
lower when compared with the CORM-3 treatment group (Figure 2.17). Such results suggest
that, with the loss of one carbonyl ligand, the reducing ability of the ruthenium complex also
decreased. Such results also further indicate that the coordinated CO is critical for the ability to
reduce an arylnitro group by the ruthenium carbonyl complex.

Figure 2.17 Fluorescence intensity changes from COFP (10 M) upon treatment with
CORM-3 and iCORM-3 in PBS (pH = 7.4, 4% DMSO) at 37 C. (ex = 440 nm, em = 522 nm,
slit widths: Wex = Wem = 10 nm)
Previously, a ruthenium (II) carbonyl complex, Ru3(CO)12, was extensively reported to
quantitatively reduce nitrobenzene to aniline in the presence of an amine under high CO pressure
(20 to 50 bar) and at high temperature (150 to 180 C).117-119 The mechanism was interpreted as
involving nitrene formation from the nitro moiety via ruthenium carbonyl complex-mediated
metallacyclization and extrusion of CO2, followed by reaction with CO/H2O to yield the
aromatic amine.118 In this case, it might be possible that CORM-2 and CORM-3 would lead to
the reduction of an arylnitro group through a similar mechanism as presented in Figure 2.18.

63
However, detailed mechanistic studies remain scarce. It should be noted that the most important
aspect of all these studies is the demonstration of a ruthenium complex as a prerequisite for
probe reduction, not necessarily in the detailed steps of the reaction. Such findings suggest that
COFP and other related nitro-based CO probes are capable of sensing only CO from rutheniumbased CO-RMs, as described in the original papers, but is not a general CO probe.

Figure 2.18 A literature proposed mechanism for the reduction of a nitro group to an
amine by ruthenium-CO complexes.118
2.2.5

Resazurin assay

Resazurin (Alamar Blue) is an N-oxide-based dye, widely used in cytotoxicity studies by
measuring mammalian cell viability and mitochondrial activity.120-122 The blue and weakly
fluorescent resazurin can be intracellularly reduced to a pink and highly fluorescent compound,
resorufin, in metabolically active cells (Figure 2.19A). In CO and CO-RMs related studies, the
resazurin reduction assay has been used to evaluate cytotoxicity.88, 120 Previously, we reported
that CORM-2 and CORM-3 could directly reduce the aromatic nitro group to an amino group
under physiological conditions via a CO-independent pathway. We wonder whether rutheniumbased CO-RMs would also lead to the reduction of N-oxide compounds, such as resazurin. If so,
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such property would affect the ability for resazurin to be as a reliable indicator of cell viability,
when CORM-2 or CORM-3 is present.

Figure 2.19 Responses of resazurin to treatment with various CO donors in PBS (0.01
M, pH = 7.4). A. Mechanism of resazurin-based bioassay. B. The turn-on fluorescence response
of 5 M resazurin to 50 M CORM-2 in PBS at 37 C (ex= 550 nm). C. The turn-on
fluorescence response of 5 M resazurin to 50 M CORM-3 in PBS at 37 C (ex= 550 nm). D.
Fluorescence response of 5 M resazurin to various concentrations of CORM-2 in PBS at 37 C
(ex= 550 nm). E. Fluorescence response of 5 M resazurin to various concentrations of CORM3 in PBS at 37 C (ex= 550 nm). F. Fluorescence responses of 5 M resazurin to 50 M of
various CO donors after 1 h incubation in PBS at 37 C (ex= 550 nm).
To test the reactivity of ruthenium-based CO-RMs with resazurin, we first incubated 5
M of resazurin with 50 M of CORM-2 or CORM-3 individually in PBS. In both cases, the
fluorescence signal at around 583 nm showed a significant increase within an hour (Figure
2.19B and 2.19C), and the color of the solution changed from blue to pink, corresponding to the
formation of resorufin (Figure 2.19A). Such changes were also dependent on the concentration
of CORM-2 and CORM-3 from 0 to 50 M (Figure 2.19D and 2.19E). Under the same
conditions, resazurin was also treated with the inactive forms of CO-RMs, iCORM-2 and
iCORM-3, neither of which significantly affected the fluorescence upon incubation with
resazurin in PBS for 1 h (Figure 2.19F). For additional control studies, we also injected 10 ml
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pure CO gas into the resazurin solution in a sealed vial to see whether CO alone would lead to
such a reduction reaction; no change in fluorescence was observed (Figure 2.19F).

Figure 2.20 Fluorescence response of 5 M resazurin to iCORM-2/CO gas (10 ml) or
iCORM-3/CO gas (10 ml) after incubations for 1 h ( ex= 550 nm).
To examine the possible reactivity from the combination of iCORMs and CO, pure CO
gas was injected together with iCORM-2 or iCORM-3 into the resazurin solution. The iCORM-3
and CO combination did not generate any fluorescent change either (Figure 2.20). Interestingly,
iCORM-2 and CO gas together led to the turn-on of resazurin (Figure 2.20). This might suggest
the catalytic role of the ruthenium core in iCORM-2, which mediates the reduction in the
presence of CO. However, to fully understand the intricate details of the mechanism as to why
CORM-2 and -3 are different, much more additional studies will be needed. We also examined
the reactivities of other non-ruthenium CO-RMs and organic CO prodrugs toward resazurin.
Manganese- and a boron-based CORMs, namely CORM-401 and CORM-A1 (Figure 2.1), did
not lead to any change in fluorescence of the resazurin solution (Figure 2.19F). Organic CO
prodrugs, CO-10350 and CO-111,123 also did not lead to an increase in fluorescent signal,
indicating a lack of chemical reaction with resazurin (Figure 2.21). The above results indicate a
CO-independent mechanism for the reduction of resazurin to resorufin by ruthenium-based CO-
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RMs. As a result, the reduction-based resazurin assay for cytotoxicity is expected to yield
convoluted results that are hard to interpret when CORM-2 or CORM-3 is present.

Figure 2.21 Fluorescence response of 5 M resazurin to incubations with 100 M of CO103 and CO-111 in PBS/DMSO (1:4) for 2 h (ex= 550 nm).
2.2.6

MTT-based assays

Another widely used cell proliferation and cytotoxicity assay is based on tetrazolium
salts, which can be reduced by cellular reductase to produce the strongly colored formazan
products. Among various tetrazolium salts, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) is the most commonly used agent, which was introduced by
Mosmann nearly two decades ago.124 In viable cells, MTT is reduced by cytoplasmic or
mitochondrial reductases to form the insoluble purple MTT formazan. Therefore, an increase in
absorbance between 550-600 nm is proportional to cell viability. The MTT assay has also been
used in studies of CO and CO donors.125-132 With the discovery of the reducing activities of
ruthenium-based CO-RMs toward aromatic nitro compound and resazurin, we also speculate
whether there is any interaction between MTT and ruthenium-based CO-RMs.
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Figure 2.22 Responses of MTT derivatives toward ruthenium-based CO-RMs. A. The
structure of MTT; UV absorption changes of 100 M MTT upon treatment with 200 M CORM2/3 and iCORM-2/3 for 30 min in PBS (0.01 M, pH = 7.4) at 37 C. B. The structure of WST-8;
UV absorption changes of 50 M WST upon treatment with 100 M CORM-2/3 and iCORM-2/3
for 30 min in PBS (0.01 M, pH = 7.4) at 37 C.
As an initial test, we simply mixed CORM-2 or CORM-3 with an MTT solution and
observed almost instantaneous color change from yellow to dark purple. Such a phenomenon is
very similar to what is expected from MTT reduction through cellular respiration. Therefore, we
conducted further characterizations by using UV spectroscopy. 100 M of MTT shows a distinct
absorption at around 400 nm in PBS solution (Figure 2.22A). Upon the addition of two
equivalents of CORM-2 or CORM-3, a new absorption peak at around 600 nm formed,
corresponding to the visible purple color (Figure 2.22A). As control experiments, we also
incubated CO-depleted iCORM-2 or iCORM-3 with MTT under the same conditions. However,
we did not observe any absorption change above 500 nm (Figure 2.22A). As a second control
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study, we added CO gas to the mixture of iCORMs (iCORM-2 or iCORM-3) and MTT to mimic
the released products from CORM-2 and CORM-3. The combination of iCORM-3 and CO gas
did not lead to UV absorption change (Figure 2.23). In contrast, 1 ml of pure CO gas caused a
slight increase in absorption at around 600 nm (Figure 2.24) when added to the mixture of
iCORM-2 and MTT. However, this change was much smaller than that caused by CORM-2. We
also treated MTT with other CO-RMs (CORM-A1 and CORM-401) and did not observe any
spectroscopic changes (Figure 2.25).

Figure 2.23 UV-vis spectra of MTT (100 μM) after treatment with iCORM-3 (200 μM) or
iCORM-3 and CO gas (10 ml) for 30 min in PBS (0.01 M, pH = 7.4) at 37 C.

Figure 2.24 UV-vis spectra of MTT (100 μM) after treatment with iCORM-2 (200 μM) or
iCORM-2 and CO gas (1 ml) for 30 min in PBS (0.01 M, pH = 7.4) at 37 C.
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Figure 2.25 UV-vis spectra of MTT (100 μM) after treatment with CORM-A1 (200 μM)
or CORM-401 (200 μM) for 30 min in PBS (0.01 M, pH = 7.4) at 37 C.
To check whether the color change of MTT caused by ruthenium based CO-RMs was due
to the MTT formazan production, the mixture of CORM-2 and MTT in DSMS-d6 (10% PBS)
was monitored by 1H-NMR. Interestingly, the chemical shift of MTT did not show any
difference after incubating with CORM-2 (Figure 2.26), although the corresponding color
change was observed. Such results indicate that the UV absorption increase between 500-600 nm
was not caused by the presumptive chemical reduction of MTT to its formazan product. We also
compared the UV spectrum of the MTT-CORM-2 mixture with that of MTT formazan, and
observed some differences in UV absorbance patterns (Figure 2.27). There are earlier literature
reports that tetrazole and formazan are able to chelate to ruthenium (II),133, 134 which might
explain the spectroscopic changes observed.
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B)

A)

Figure 2.26 1H NMR spectrum of A) 40 mM MTT and B) Mixture of 40 mM MTT/20 mM
CORM-2 (2:1) in DMSO-d6 (10% PBS in D2O, pH = 7.4).

Figure 2.27 UV-vis spectra of MTT formazan (100 μM) and MTT-CORM-2 mixture (100
μM MTT upon treatment with 50 μM CORM-2 for 30 min at 37 C) in ACN.
For the next step, we also studied the UV spectroscopic changes of MTT formazan when
treated with CORM-2 and CORM-3. As shown in Figure 2.28A, in the presence of 100 M of
CORM-2, the peak intensity of MTT formazan gradually decreased. At the 50-min time point,
the peak at 600 nm almost disappeared completely. 100 M of CORM-3 also led to the
disappearance of the peak corresponding to MTT formazan within 1 h (Figure 2.28B).
Additionally, we also used iCORM-2 and iCORM-3 in control studies. iCORM-2 also led to a
decrease of the MTT formazan absorption peak. However, the effect was only 40% of that of
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CORM-2 at the 90-min time point (Figure 2.29C). iCORM-3, on the other hand, induced
spectroscopic changes of MTT formazan to the same magnitude as that of CORM-3 (Figure
2.28D). Such results mean that when MTT is used in cytotoxicity studies, CORM-2 and CORM3 will interfere with the outcome by perturbing the spectroscopic properties of MTT and MTT
formazan.
A)

C)

B)

D)

Figure 2.28 UV-vis spectra of MTT formazan (50 μM) upon treatment with 100 μM of A)
CORM-2; B) CORM-3; C) iCORM-2; D) iCORM-3 in isopropanol/PBS=1:1 at 37 C.
Ruthenium-based CO-RMs have also been tested with another commonly used watersoluble tetrazolium compound, WST-8, which is the active ingredient in the commonly used
CCK-8 assay. Similar to MTT, WST-8 also serves as a redox indicator to represent cell viability
and has been widely used in CORM-based cytotoxicity studies.135-139 Upon addition of 100 M
of CORM-2 or CORM-3 to WST-8 in PBS, a new peak at 450 nm appeared within 30 min of
incubation at 37 C (Figure 2.22B). However, inactive forms of CORM-2 and CORM-3,
iCORM-2 and iCORM-3 failed to produce any response under the same conditions (Figure
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2.22B). It should be noted that the readouts from CCK-8 is based on the absorbance change of
WST-8 at 460 nm in a generally accepted protocol. As such, the spectroscopic changes caused
by CORM-2 and CORM-3 are expected to interfere with the results and interpretation of
cytotoxicity studies using the CCK-8 assay. Our results show that ruthenium-based CO-RMs can
cause significant changes on the spectroscopic properties of tetrazolium salts (MTT and WST-8)
and the MTT formazan product, and are expected to affect the absorption readout in MTT- and
WST-8-based assays.
2.2.7

Consumption of nitrite

CORM-2 and CORM-3 have been extensively reported to inhibit NO production
triggered by various inflammatory stimulators in vivo.140, 141 Due to the rapid oxidation of NO to
nitrite by oxygen, the NO concentration in biological studies is usually determined by measuring
its nitrite content as a surrogate. Acting as reducing agents to both aryl nitro and N-oxide groups,
we are interested in evaluating if CORM-2/CORM-3 can also directly react with nitrite, which is
the key analyte/ingredient for determining NO concentration. To start with, 100 M of nitrite
was incubated with CORM-2 in PBS for 5 h and 24 h at 37 C, followed by determining the
nitrite concentration using the Griess test. To our surprise, 50 and 100 M CORM-2 dropped the
nitrite concentration by 14% and 15% at the 5-h point and 21% and 34% at the 24-h point,
respectively (Figure 2.29A, 2.30A). iCORM-2 also caused a comparable decrease in nitrite
concentration. 100 M iCORM-2 decreased the nitrite concentration by almost 48% after 24 h
incubation, which was even lower than that caused by CORM-2 (Figure 2.29A).
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Figure 2.29 Effects of ruthenium-based CO-RMs of on nitrite. A. A solution of 100 M
nitrite in PBS was incubated with CORM-2 and iCORM-2 for 24 h at 37 C and then nitrite
concentrations were determined by the Griess test. B. A solution of 100 M nitrite in PBS was
incubated with CORM-3 and iCORM-3 for 24 h at 37 C and then nitrite concentrations were
determined by the Griess test. Values are means ± SD. n = 3. *P<0.01, **P<0.001 versus the
vehicle group. #P<0.001 between CORMs and iCORMs.
CORM-3 was also examined under the same conditions. Upon treatment with 100 M of
CORM-3 for 5 h and 24 h, the nitrite concentration was reduced by 14% and 38%, respectively
(Figure 2.29B, 2.30B). Under the same conditions, iCORM-3 did not lead to a significant
decrease after 5 h of treatment; however, at the 24-h point, the nitrite concentration decreased by
22%. Such results suggest a weaker reactivity of iCORM-3 compared with CORM-3 (Figure
2.30B). Our results indicate that both CORM-2 and CORM-3 directly consume nitrite in vitro.
iCORM-2 and iCORM-3 are not considered to be suitable controls for CORM-2,3 in studying
CO’s effect on NO production.
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Figure 2.30 Effect of ruthenium-based CO-RMs on nitrite. A. 100 M nitrite PBS
solution was incubated with CORM-2 or iCORM-2 for 5 h at 37 C and nitrite concentrations
were determined by the Griess test. B. 100 M nitrite PBS solution was incubated with CORM-3
or iCORM-3 for 5 h at 37 C. Nitrite concentrations were determined by the Griess test. Values
are means ± SD. n = 3. *P<0.05, **P<0.01, ***P<0.001 versus the vehicle group.
2.2.8

Azide-based H2S probe

Figure 2.31 Responses of DNS-Az toward ruthenium-based CO-RMs. A. The structure
of DNS-Az. B. Fluorescence response of 100 M DNS-Az to 100 M CORM-2 and iCORM-2 in
PBS/ACN (1:1) after incubation for 20 min at r.t. (ex= 360 nm). C. Fluorescence response of
100 M DNS-Az to various concentrations of CORM-2, 100 M iCORM-2 and 10 ml CO gas in
PBS/ACN (1:1) after incubation for 20 min at r.t. (ex= 360 nm). D. Fluorescence response of
100 M DNS-Az to 100 M CORM-3 and iCORM-3 in PBS/ACN (1:1) after incubation for 20
min at r.t. (ex= 360 nm).
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Activated azido groups are known to be reduced by H2S, and such reactivity is widely
used in designing H2S fluorescent probes.142-144 Both of DNS-Az142 and AzMc145 are H2S
fluorescent probes bearing an azido group attached to a fluorophore (Figure 2.31A, 2.32A). The
reduction of such an azido group to the corresponding amino group by H2S is the basis for
fluorescence turn-on and thus sulfide detection. We were interested in seeing if ruthenium-based
CO-RMs could reduce these probes. Therefore, we first studied the response from DNS-Az in
the presence of CORM-2. Upon incubation with 100 M of CORM-2 in PBS/ACN (1:1), the
fluorescence intensity of DNS-Az significantly increased within the first 20 min to reach a
plateau (Figure 2.31B, 2.32A). Concentration-dependent fluorescence intensity changes were
also observed in the presence of 20 to 100 M CORM-2 (Figure 2.31C). Incubations with either
iCORM-2 or CO gas did not lead to any fluorescence changes (Figure 2.31C). 100 M of
CORM-3 also caused an increase in fluorescence intensity of the DNS-Az solution within 20
min, while iCORM-3 did not show any reactivity (Figure 2.31D, 2.31B).
B)

A)

20 min
20 min

5 min
5 min

Figure 2.32 Turn-on fluorescence response of 100 M DNS-Az to 100 M of A) CORM-2
and B) CORM-3 in PBS (0.01 M, pH = 7.4)/ACN (1:1) at r.t. (ex= 360 nm).
Next, AzMC was tested with CORM-2 and CORM-3. Both CORM-2 and CORM-3 led
to an increase of the fluorescence intensity of AzMC within 1 h of incubation at room
temperature, while incubation with iCORM-2 and iCORM-3 resulted in minimal increases in the
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fluorescent intensity (Figure 2.33). These results suggest that CORM-2 and CORM-3 are capable
of reducing the azido groups presented in two representative H2S probes, DNS-Az and AzMc,
while iCORM-2/3 failed to do so. As a result, we recommend azido-based H2S probes and
CORM-2/3 not be used together in studying the cross-talk between CO and H2S.

Figure 2.33 Responses of AzMc toward ruthenium-based CO-RMs in PBS (0.01 M, pH
= 7.4). A. The structure of AzMC. B. Fluorescence response of 10 M AzMC to 100 M CORM-2
and iCORM-2 in PBS after incubation for 1 h at r.t. ( ex= 365 nm). C. Turn-on fluorescence
response of 10 M AzMC to 100 M CORM-2 in PBS at r.t. (ex= 365 nm). D. Fluorescence
response of 10 M AzMC to 100 M CORM-3 and iCORM-3 in PBS after incubation for 1 h at
r.t. (ex= 365 nm).
2.3

Conclusions
In this chapter, we studied CO-independent reactivities of ruthenium-based CO-RMs

including: i) reduction of nitro-based CO probes; ii) reduction of resazurin; iii) perturbation of
the spectroscopic properties of tetrazolium salts, MTT and WST-8; iv) consumption of nitrites in
vitro and v) and reduction of azide-based H2S fluorescent probes, DNS-Az and AzMc. These
reagents and related assays have been used in assessing CO’s biological effects. As such, we
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recommend cautious evaluation of the results when CORM-2/-3 are used in combination of these
reagents.
2.4

Experimental part
2.4.1

General information

All reagents and solvents were of reagent grade from commercial suppliers (Sigma
Aldrich and etc.). 1H (400 MHz) and 13C (100 MHz) NMR spectra were performed on a Bruker400 spectrometer. Mass spectral analyses were performed on an ABI API 3200 (ESI-Triple
Quadruple) by the Georgia State University Mass Spectrometry Facilities. Fluorescence spectra
were recorded on a Shimadzu RF-5301PC fluorometer. Absorption spectra were measured on
Varian Cary 100 Bio UV-Visible spectrophotometer. CO-RMs (CORM-2, CORM-3, CORM-A1
and CORM-401) and H2S probe (AzMC) were purchased from Sigma-Aldrich and were used
without purification. Pure CO gas was purchased from Airgas company. iCORM-2 and iCORM3 were prepared according to the literature procedures.58, 146 CO prodrugs (CO-103 and CO111)73, 123, COP-178 and H2S probe (DNS-Az)142 were synthesized according to the literature
procedures. 2-Dicyanomethylen-3-cyano-4,5,5-trimethyl-2, 5-dihydrofurane was synthesized
according to the reported procedures.147
2.4.2

Synthesis

5-nitro-2-phenyl-1H-benzo[de]isoquinoline-1,3(2H)-dione (COFP) was synthesized
according to a reported procedure.148 3-Nitro-1,8-naphthalic anhydride (0.62 mmol, 150 mg) and
aniline (0.62 mmol, 58 mg) were refluxed in 4 ml acetic acid for 4 h. 20 ml water was added at
room temperature and the formed yellow solid was filtered and washed with water. The crude
product was purified by silica gel column chromatography to yield the pure product as white
solid (103 mg, 52 %). 1H NMR (DMSO-D6) δ 9.51 (s, 1H), 8.95 (s, 1H), 8.81 (d, J = 8.4 Hz,
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1H), 8.68 (d, J = 7.2 Hz, 1H), 8.08 (t, J = 8.0 Hz, 1H), 7.56-7.48 (m, 3H), 7.41 (d, J = 7.2 Hz,
2H). 13C NMR (DMSO) δ 163.2, 162.7, 145.9, 136.5, 135.7, 134.0, 131.1, 130.1, 129.9, 129.4,
129.1, 128.6, 124.7, 123.3, 122.9. HRMS calculated for C18H10N2O4Na [M+Na]+: m/z 341.0540,
found 341.0538. HRMS calculated for C18H10N2O4Na [M+Na]+: m/z 341.0540, found 341.0538.
2-(2-morpholinoethyl)-5-nitro-1H-benzo[de]isoquinoline-1,3(2H)-dione (LysoFP-NO2)
was synthesized following a modified reported procedure.85 To a solution of 3-nitro-1,8naphthalic anhydride (0.33 mmol, 80 mg) in 20 ml ethanol was added 4-(2-aminoethyl)
morpholine (0.39 mmol, 51 mg) dropwise in 3 ml ethanol. The solution was allowed to stir for
40 min at r.t. and then heated to reflux for another 2 h. The formed solid was filtered and washed
with 5 ml cold ethanol. The crude product was purified by silica gel column chromatography to
yield the pure product (42 mg, 36%). 1H NMR (CDCl3) δ 9.30 (d, J = 2.2 Hz, 1H), 9.13 (d, J =
2.2 Hz, 1H), 8.93-8.61 (m, 1H), 8.43 (d, J = 8.2 Hz, 1H), 8.07-7.77 (m, 1H), 4.36 (t, J = 6.7 Hz,
2H), 3.80-3.50 (m, 4H), 2.72 (t, J = 6.6 Hz, 2H), 2.58 (s, 4H). 13C NMR (CDCl3) δ 163.27,
146.51, 135.71, 134.57, 131.1, 130.3, 129.1, 124.8, 124.3, 123.3, 77.4, 77.1, 76.8, 67.1, 56.1,
53.9, 37.7. HRMS calculated for C18H18N3O5 [M+H]+: m/z 356.1237, found 356.1246.
(E)-2-(3-cyano-4-(3-hydroxy-4-nitrostyryl)-5,5-dimethylfuran-2(5H)ylidene)malononitrile (NIR-CO) was synthesized following a literature procedure.86 To a
solution of 3-hydroxy-4-nitrobenzaldehyde (105 mg, 0.63 mmol) in 5 ml ethanol was added
piperidine (53 mg, 0.63 mmol) and 2-dicyanomethylen-3-cyano-4,5,5-trimethyl-2, 5dihydrofurane (125 mg, 0.63 mmol). The mixture was allowed to stir at r.t. for 12 h and then
filtrated. The residue was purified by silica gel column chromatography to yield the pure product
(80 mg, 36%). 1H NMR (DMSO-D6) δ 7.98 (d, J = 8.8 Hz, 1H), 7.81 (d, J = 16.8 Hz, 1H), 7.51
(d, J = 8.4 Hz, 2H), 7.24 (d, J = 16.4 Hz, 1H), 1.78 (s, 6H). 13C NMR (DMSO-D6) δ 40.15 (s),
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39.88 (d, J = 11.4 Hz), 39.73 (s), 39.52 (s), 39.23 (d, J = 15.8 Hz), 39.10 (s), 38.82 (d, J = 14.8
Hz). HRMS calcd for C18H11N4O4 [M-H]-: m/z 347.0780, found 347.0774.
cis-RuCl2(DMSO)4 (Complex D) was synthesized according to a reported procedure.116
Briefly, 100 mg RuCl3.xH2O was dissolved in 4 ml DMSO and stirred at reflux for 1 h. The
color of the reaction mixture changed from deep brown to light yellow. After cooling to room
temperature, the reaction mixture was cooled at -20 °C; the crystalized bright yellow solid was
filtered and washed with acetone followed by drying in vacuum to afford 147 mg (63%) of a
bright yellow solid. NMR shown the aqua species cis,fac-[RuCl2(dmso-S)3(H2O)] after dissolved
in D2O as suggested. 1H NMR (D2O) δ 3.48 (s, 6H), 3.46 (s, 6H), 3.37 (s, 6H), 2.70 (s, 6H). 13C
NMR (D2O) δ 46.73, 45.70, 44.31, 38.67.
N-isobutyl-4-nitrobenzamide (PNB) To a solution of 4-nitrobenzoic acid (200 mg, 1.2
mmol) in 5 ml DCM was added EDC (343 mg, 1.8 mmol), DMAP (219 mg, 1.8 mmol),
triethylamine (181 mg, 1.8 mmol) and isobutylamine (87.6 mg, 1.2 mmol). The mixture was
allowed to stir at r.t. for 12 h. The reaction solution was diluted with 15 ml DCM and washed
with 10 ml 0.1 M HCl. The organic layer was dried over anhydrous Na2SO4 and concentrated
under reduced pressure. The residue was purified by silica gel column chromatography to yield
the pure product as a white solid (205 mg, 77 %). 1H NMR (CDCl3) δ 8.15 (d, J = 8.8 Hz, 2H),
7.90 (d, J = 8.4 Hz, 2H), 7.09 (s, 1H), 3.21 (t, J = 6.4 Hz, 2H), 1.87-1.84 (m, 1H), 0.90 (d, J =
6.8 Hz, 6H). 13C NMR (CDCl3) δ 165.8, 149.6, 140.6, 128.2, 123.9, 47.78, 28.7 20.3. HRMS
calcd for C11H14N2O3 [M+H]+ 223.1083, found 223.1093.
4-amino-N-isobutylbenzamide (PAB) To a solution of PNB (45 mg, 0.18 mmol) in 1.8
ml acetone/water (5:1) was added zinc powder (117 mg, 1.8 mmol) and ammonium chloride
(144 mg. 2.7 mmol). The mixture was vigorously shaken at room temperature for 1 min and then
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filtered. The filtrate was diluted with 10 ml ethyl acetate and washed with 5 ml saturated
NaHCO3 solution. The organic layer was dried over anhydrous Na2SO4 and concentrated under
reduced pressure. The residue was purified by silica gel column chromatography to yield the
pure product as a white solid (23 mg, 67%). 1H NMR (Methanol-d4) δ 8.13 (s, 1H), 7.59 (d, J =
8.4 Hz, 2H), 6.66 (d, J = 8.8 Hz, 2H), 3.15 (t, J = 6.4 Hz, 2H), 1.92-1.86 (m, 1H), 0.94 (d, J = 6.8
Hz, 6H). 13C NMR (Methanol-d4) δ 170.6, 153.0, 129.8, 123.5, 114.7, 48.3, 29.9, 20.6. HRMS
calcd for C11H16N2O [M-H]-: m/z 191.1186, found 191.1184.
2.4.3

Preparation of stock solutions

COFP, LysoFP-NO2 and NIR-CO were dissolved in DMSO to afford a 500-M stock
solution; COP-1 was dissolved in DMSO to afford a 200-M stock solution. Stock solutions of
CORM-2 (10 mM), CORM-401 (10 mM), CO-103 (10 mM), CO-111 (10 mM), resazurin (1
mM) and AzMC (1 mM) were prepared in DMSO. 10 mM Stock solutions of CORM-3, CORMA1, MTT and WST-8 were prepared in water. MTT formazan was dissolved in isopropanol to
afford a 2 mM stock solution. DNS-Az was dissolved in ethanol to afford a 30 mM stock
solution.
2.4.4

HPLC and LC-MS analysis of reduction of PNB by CORM-3

Stock solution preparation: PNB was dissolved in DMSO to afford a 10 mM stock
solution. CORM-3 was dissolved in distilled water to afford a 100 mM stock solution.
20 μL of PNB stock solution was diluted with 360 μL PBS (pH 7.4), followed by
addition of 20 L of the CORM-3 stock solution. The final concentrations of PNB and CORM-3
were 500 M and 5 mM respectively. The reaction mixture was incubated at 37°C and
monitored by HPLC (gradient: ACN in water (0.1%TFA) 5-95% in 10 min, C18 4.6*150 mm
column). For CO gas treatment, pure CO gas was bubbled through the PNB solution (500 μM in
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PBS, pH 7.4 with 5% DMSO) for 2 h at 37 °C. The formation of PAB was identified by HPLC
(with PAB reference compound) and LC/MS.
2.4.5

CO gas treatment

To a 6-ml headspace vial, 2 ml of the sample solution was added. 1 to 10 ml of pure CO
gas was directly bubbled into the solution by a headspace gas syringe. The resulting solution was
further incubated under various conditions followed by acquisition of the spectroscopic spectra.
2.4.6

Griess test

Nitrite concentrations were measured by the Griess method. According to the vendor’s
procedure, 50 L sample solution was mixed with 25 L Griess reagent R1 (No. 780018,
Cayman Chemical) and 25 L Griess reagent R2 (No. 780020, Cayman Chemical). The resulting
mixture was incubated for 10 min before measuring the absorbance at 530 nm. The nitrite
concentrations were quantified by using a standard curve.
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APPENDICES
Appendix A NMR Spectrum of BW-GP-401 and Trapped prodruct A.
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Appendix B NMR Spectrum of persulfide prodrugs and trapped products.
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Appendix C NMR Spectrum of nitro-based CO probes
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